Plasma-Enabled Carbon Nanostructures for Early Diagnosis of Neurodegenerative Diseases

Shafique Pineda 1,2, Zhao Jun Han 1,* and Kostya (Ken) Ostrikov 1,2,3

1 Plasma Nanoscience Centre Australia (PNCA), CSIRO Materials Science and Engineering, P.O. Box 218, Lindfield, NSW 2070, Australia; E-Mails: shafique.pineda@csiro.au (S.P.); kostya.ostrikov@csiro.au (K.K.O.)
2 Plasma Nanoscience@Complex Systems, School of Physics, the University of Sydney, Sydney, NSW 2006, Australia
3 School of Chemistry, Physics, and Mechanical Engineering, Queensland University of Technology, Brisbane, QLD 4000, Australia

* Author to whom correspondence should be addressed; E-Mail: zhaojun.han@csiro.au; Tel.: +61-2-9413-7382; Fax: +61-2-9413-7200.

Received: 27 March 2014; in revised form: 18 June 2014 / Accepted: 20 June 2014 / Published: 25 June 2014

Abstract: Carbon nanostructures (CNs) are amongst the most promising biorecognition nanomaterials due to their unprecedented optical, electrical and structural properties. As such, CNs may be harnessed to tackle the detrimental public health and socio-economic adversities associated with neurodegenerative diseases (NDs). In particular, CNs may be tailored for a specific determination of biomarkers indicative of NDs. However, the realization of such a biosensor represents a significant technological challenge in the uniform fabrication of CNs with outstanding qualities in order to facilitate a highly-sensitive detection of biomarkers suspended in complex biological environments. Notably, the versatility of plasma-based techniques for the synthesis and surface modification of CNs may be embraced to optimize the biorecognition performance and capabilities. This review surveys the recent advances in CN-based biosensors, and highlights the benefits of plasma-processing techniques to enable, enhance, and tailor the performance and optimize the fabrication of CNs, towards the construction of biosensors with unparalleled performance for the early diagnosis of NDs, via a plethora of energy-efficient, environmentally-benign, and inexpensive approaches.
Keywords: low-temperature plasmas; carbon nanostructures; plasma nanoscience; graphene; nanotubes; nanosheets; nanowalls; biosensor; neurodegenerative diseases

1. Introduction

Neurodegenerative diseases (NDs) such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are becoming more prevalent with the ageing population. At present, over 40 million individuals worldwide are affected by AD or PD [1,2]. More critically, this amassing population of sufferers may see a three-fold increase by 2050 [3,4]. In addition to human suffering, this represents not only a significant loss in productivity, but also a huge burden on the health care system and the economy [5]. Whilst a cure is not yet available, the symptoms associated with ND may be more effectively managed with early intervention therapies and lifestyle adjustments if they are diagnosed as early as possible.

Unfortunately, NDs are usually first diagnosed symptomatically, once the disease has progressed to the point where it is noticeable. The identification of clinical markers (i.e., Lewy bodies in the PD case [6] and Lewy-body dementia or plaques in the AD case [7,8]) is typically only possible post-mortem. Biomarkers, on the other hand, are good candidates for the early detection of ND. Early detection will enable medical practitioners to implement treatment strategies such as brain exercises and physical fitness regimes, and identify sufferers who may respond to drugs (e.g., for AD [9–11], and PD [12–14]) designed to slow the progression of the disease. This points to the critical importance of developing practical advanced sensors capable of detecting low concentrations of ND-related biomarkers (including, but not limited to, beta-Amyloid (Aβ) [15,16], alpha-Synuclein [17,18], mtDNA [19], and phospholipids [20]), and distinguish between their various mutated and misfolded forms (e.g., monomers, protofibrils, oligomers, and fibrils) in complex mixtures such as blood and cerebrospinal fluid (CSF), for a presymptomatic diagnosis and progressive monitoring of AD and PD.

1.1. Biosensors

Fundamentally, a biosensor is a device comprised of two elements—a biomolecular receptor capable of specific reaction with the target analyte, and a transducer which processes the biorecognition event into a measurable signal. Indeed, a diverse spectrum of electrochemical [21–26] and optoelectrical [27–29] biosensors has been recently developed for the detection of biomarkers indicative of AD or PD. However, these biosensors fall short in addressing one or more key criteria of device performance and fabrication. In particular, this includes a high sensitivity and specificity in physiochemical environments (i.e., blood or CSF), a rapid sensor response and regeneration, and an inexpensive device fabrication. Consequently, future innovations in the design of novel advanced materials towards the optimization of biosensors for ND biomarkers remain highly warranted.

1.2. Advanced Materials: Carbon Nanostructures

Notably, carbon nanostructures (CNs) (e.g., nanotubes, nanosheets, and nanowalls) inherit a multitude of characteristics that enable their versatility to simultaneously play the role of a specific receptor and a sensitive transducer. For instance, the mechanical robustness, high electrical conductivity,
superior optical properties, and ease of functionality of CNs, have been harnessed to realize a plethora of hierarchical biorecognition nanocomposites (see Sections 2.1, 2.2, 3.1, 3.2, and 4.1 below) which may be tailored for the determination of AD or PD biomarkers. Correspondingly, this highlights the necessity for a deterministic, resource-efficient, and practical synthesis for these hybrid nanostructures.

1.3. From Fabrication to Performance: The Plasma Advantage

Conventional approaches for the synthesis of carbon-based biorecognition structures have involved techniques such as lithography, wet chemical processing, and chemical vapor deposition (CVD). However, not only are these methods time consuming and energy-inefficient, but also the harsh environments involved have been responsible for inducing substrate damage, unwanted impurities, and non-uniformity in yield. Consequently, this leads to a poor reproducibility in device fabrication and a compromised biosensing performance. On the other hand, plasma-based techniques [30–33] for fabrication and surface treatment may be implemented to enable, enhance, and tailor the device performance and optimize the fabrication processes of CNs towards the construction of biosensors with superior properties, via a plethora of resource-efficient, eco-friendly, and inexpensive approaches (see Sections 2.3, 3.3, and 4.2 below).

2. Graphene

Graphene, a single-layer two-dimensional (2D) honeycomb lattice of $sp^2$-hybridized carbon atoms [34–36], inherits an exceptional tensile strength [37], large specific surface area [38–40], ease of functionality [41,42], tunable band gap [43–45], low electrical noise [46,47], ballistic charge transport [48,49], and high charge carrier concentrations at room temperature [46,50]. Consequently, a wide variety of graphene-based electrical (Section 2.1) and optical (Section 2.2) biosensors have been realized through its unique physicochemical properties.

2.1. Graphene-Based Electrical Biosensors

Graphene-based field effect transistors (G-FETs) have been essential towards the developments for a label-free and real-time determination of biological complexes. In G-FETs, the surface of graphene serves as the interfacial element for biorecognition and transduction. Typically, target analytes are selectively detected by a specific binding with complementary biomolecules functionalized on the surface of graphene. In particular, a charged molecule (e.g., protein, DNA) adsorbed on the surface of graphene induces a perturbation in the local charge density, leading to a change in the channel conductance. In G-FET DNA biosensors, selectivity is enabled through the hybridization between complementary DNAs. For instance, single-stranded (ss) DNAs have been tethered on the surface of chemically modified graphene through linker molecules for a specific detection of the complementary DNA [51–54]. Notably, the first G-FET DNA biosensor was established by Mohanty et al. [51], where graphene oxide (GO) sheets were prepared by a modified Hummers method [55–57] and backgated with silica. The functional groups on GO were utilized to immobilize single-stranded fluorescent DNA probes for a selective detection of complementary target DNAs through successive base-pairing hybridization/dehybridization interactions and restorations in GO conductivity. Subsequently, innovations
in DNA G-FETs including electrolyte-gated setups [58,59], CVD-prepared graphene for low-noise performance [60], and an increased loading of probe DNAs through nanoparticle (NP) functionalized graphene-based substrates [58,59], have driven improvements in the detection limit of DNAs to the nM and pM concentrations. Most recently, Cai et al. [61] have designed a reduced graphene oxide (RGO)-FET DNA biosensor capable of selectively identifying single-based mismatched DNAs and noncomplementary DNAs, with a resolution of 100 fM, which is one order of magnitude lower than previously reported G-FET DNA biosensors. In this biosensor, peptide nucleic acid (PNA) (instead of ssDNA) was employed as the capture probe, and DNA recognition was achieved through PNA-DNA hybridization on the RGO surface. Above all, these G-FETs with the capability of sequence-specific DNA recognition may be tailored for a label-free and real-time determination of DNA mutations indicative of AD or PD.

A similar biorecognition protocol has been developed for proteins (i.e., immunoglobulins), where selectivity was enabled through antibody-antigen [62–65] or protein-aptamer [66–69] binding at the graphene interface. Moreover, the probe biomolecules (e.g., antibodies, aptamers, ssDNAs) may be labeled on the surface of chemically modified graphene via (i) chemical linkers [65,67,70]; or (ii) conjugation with NPs adsorbed on its surface [63,64,70]. The chemical-linker-based approach has been adopted by Kurkina et al. [65] to realize a RGO-FET immunosensor for Aβ peptides. The surface of RGO was initially functionalized with Staphylococcus aureus protein A (SpA) through carbodiimide coupling [71], and subsequently, anti-Aβ-antibodies were immobilized on SpA-RGO through the specificity of SpA with the Fc antibody fragments [72]. This immunosensor reported a detection limit of 1 fM Aβ—an order of magnitude improvement compared to commercial ELISA assays for Aβ quantification in biological fluids [73]. In the second approach based on conjugated NPs, not only do NPs increase the load of probe biomolecules, it also enables an outward orientation of binding sites (i.e., antibody Fab region), and hence optimizes the device sensitivity by maximizing the number of available capture sites for the target proteins. For instance, Mao et al. [63,64] and Myung et al. [70] have established a highly-sensitive and selective G-FET protein biosensor, based on RGO decorated with AuNP-antibody conjugates for the determination of complementary antigens. The biorecognition substrate was also prepared by thermal reduction from GO [63], whereby a detection limit in the order of ng/mL was deduced, and the specificity in antibody-antigen binding mechanism was demonstrated for the immobilization of non-complementary antigens including immunoglobulin-G (Ig-G), immunoglobulin-M (Ig-M) and horseradish peroxide (HRP). In Figure 1a the fabrication of a similar NP composite-based G-FET immunosensor [70] is illustrated, where reduced graphene oxide (RGO)-encapsulated nanoparticle (NP) arrays were implemented for a highly sensitive, selective and label-free detection of breast cancer biomarkers. Moreover, the limit of protein detection may be enhanced by reducing the effects of Debye screening on the immobilized target proteins. In particular, this has been demonstrated by Kim et al. [62,68], where aptamers (short oligonucleotides) were utilized as probe biomolecules to achieve detection limits in the femto- and atto-molar ranges.

On the other hand, graphene-based electrochemical (GEC) biosensors rely on redox reactions between the probe and target biomolecules for transduction. In comparison with G-FETs, GEC biosensors are attractive as they present a simpler and hence less expensive electrode fabrication. Consequently, a diverse spectrum of highly-selective and sensitive GEC biosensors have been developed for the determination of disease-specific protein biomarkers [74–77], in conjunction with
nucleic acids (i.e., DNA bases) and DNA sequences [78–90], which may be tailored for the realization of single nucleotide polymorphism (SNP) assays for DNA mutations correlated with the development of AD or PD.

**Figure 1.** Graphene-based field effect transistors (FET), electrochemical, fluorescent resonance energy transfer (FRET), and surface enhanced Raman scattering (SERS)-active biosensing platforms. (a) A reduced graphene oxide (RGO)-encapsulated nanoparticle (NP) array for a highly sensitive, selective and label-free detection of breast cancer biomarkers. Reproduced from [70]; (b) Graphene oxide nanoplatelets (GONPs) utilized as electroactive labels for the detection of thrombin (THR). Reproduced from [91]; (c) Schematic for the preparation of DNA-CdTe quantum dots (QDs) for a FRET assay of DNAs. Reproduced from [92]; (d) Preparation of a multiplexed SERS-active substrate based on AuNP-decorated DNAs. Reproduced from [93].
The properties of graphene, namely, its diverse functionalities, two-dimensional structure, and high electrical conductivity, have been crucial towards the enhancement in selectivity and sensitivity of electrochemical biosensors. In particular, graphene is typically integrated as an electrode coating in GEC biosensors as its surface may be functionalized with chemical linkers [75–77, 94] or nanocomposites (e.g., nanoparticles, nanorods) [87, 89, 95], to facilitate the adsorption or immobilization of probe biomolecules (e.g., antibodies, ssDNAs) for a highly-sensitive and specific assay of the target analytes. For instance, a label-free GEC immunosensor with a resolution of 0.012 U/mL for the cancer biomarker, carbohydrate antigen 15-3 (CA 15-3), was reported [75]. A glassy carbon electrode was coated with nitrogen-dope graphene sheets for the immobilization of CA 15-3 specific antibodies through its Fc site. The modified electrode was subsequently immersed in BSA to prevent non-specific binding, before the target antigens were introduced. While metal nanoparticles have been commonly employed as electroactive labels in electrochemical sandwich assays [96, 97], a novel aptasensor which exploits the inherent electroactivity of graphene oxide nanoplatelets (GONPs) for labeling was recently developed (Figure 1b) [91]. In this assay, the basis of detection lies in the ability of GO to be electrochemically reduced to provide a well-defined reduction “wave”, in which a single GONP (dimension 50 × 50 nm) induces a reduction signal by accepting electrons from the modified electrode surface. By using GONPs as an inherently electroactive label, thrombin detection was demonstrated in the concentration range of 3 pM to 0.3 µM, with good selectivity of the aptamer towards interferences by bovine serum albumin (BSA), IgG and avidin. Most importantly, these GEC biorecognition platforms may be adapted to the determination of protein biomarkers and DNA mutations indicative of AD or PD.

2.2. Graphene-Based Optical Biosensors

Optical biosensors have predominantly capitalized on the surface plasmonic [98, 99] and dye-quenching properties [100–102] of graphene to design a diverse range of highly-sensitive, very specific, extremely fast and low-noise biosensors for proteins and DNAs. The mechanisms involved include fluorescent...
resonance energy transfer (FRET) [103–107], surface plasmon resonance (SPR) [108–111], surface enhanced Raman scattering (SERS) [93,112,113], and several other protocols.

By exploiting the photoluminescence of GO and quenching ability of gold nanoparticles (AuNPs) for organic fluorophores, a series of FRET-based biosensors of GO arrays were realized towards aptasensing [105] and immunosensing [106] of proteins, and for the detection of sequence-specific DNA hybridization [107,114]. Correspondingly, probe biomolecules including aptamers [105], antibodies [106], ssDNAs and molecular beacons (MBs) [115,116] have been utilized in these selective FRET assays of proteins and nucleic acids (e.g., DNA bases and sequences). Generally, the capture of a target biomolecule is verified by the fluorescence quenching of GO by FRET between the fluorescent (i.e., NP)-tagged target and GO sheets. In Figure 1c, a typical FRET assay is illustrated for DNA-CdTe quantum dot (QD) conjugates with graphene [89]. In the case of Liu et al. [107], probe DNAs linked to the surface of GO by carbodiimide chemistry were hybridized with AuNPs labeled with the complementary target DNA strands, which correspondingly led to a decrease in fluorescence emission intensity from the GO arrays. Based on a similar principle of FRET, Jung et al. [106] have fabricated an alternate biorecognition assay for immunosensing. This biosensor was realized through the synthesis of AuNP-antibody (Ab) conjugates (Ab-AuNP-DNA complexes) via ssDNA linkers. In particular, DNA linkers were utilized to provide a control of distance between Ab and AuNPs, such that AuNPs could quench the fluorescence while bound to the GO surface. The high affinity of amino functional groups of DNA nucleotides for AuNPs led to an enhancement in the quenching efficiency of GO. Consequently, target biomolecules on the GO surface were identified through a specific binding with Ab-dsDNA-AuNP complexes, which resulted in a reduction of fluorescence emission by the GO arrays. Furthermore, while fluorescent tags such as quantum dots [104,117] and NPs have been commonly employed in FRET-based assays, a novel protocol for sequence-specific DNA sensing was recently developed [103], which utilizes the fluorescence from aggregation-induced emission (AIE) molecules. In particular, 9,10-distyrylanthracene with two ammonium groups (DSAI) were used in a novel AIE probe, and the fluorescent aptasensor based on DSAI and GO was developed for selective and sensitive detection of targeted DNA and thrombin proteins.

On the other hand, SPR biosensors utilize the propagation of surface plasmon polariton (SPP) waves to probe the interactions between biomolecules and the sensing surface. In particular, graphene has been employed as a functional coating to enhance the SPR signal and the immobilization of probe biomolecules. For instance, Wu et al. [111] have achieved a superior performance in biomolecular recognition for graphene-on-gold compared to gold-only platforms in SPR-based biosensors. As the graphene coating improves the propagation of surface plasmon polaritons, it consequently enhances the device sensitivity to changes in its refractive index. Additionally, the detection of biomolecules with carbon-based ring structures (e.g., ssDNA) was discovered to be well supported by graphene-on-Au SPR biosensors. This stems from an increased bioaffinity to the surface of graphene through π-stacking of sp3 orbitals, and consequently enhances the device sensitivity. On the detection of proteins, Zhang et al. [109,110] have established an SPR biosensor composed of GO decorated with gold nanostructure-antibody conjugates for a specific measurement of the antigen content. The large specific surface area and abundant oxygen-containing functional groups of GO had facilitated the immobilization of gold nanorod (AuNR)–antibody conjugates on its surface [110]. Meanwhile, AuNRs anchored to the GO surface function as SPR signal enhancers which greatly improved sensitivities in
the determination of transferrin, as evident by the limit of detection which was reported to be 32 times lower than that obtained with continuous Au films. Moreover, Wang et al. [108] have demonstrated a label-free and regenerative SPR biosensor for α-thrombin, composed of noncovalently adsorbed α-thrombin-specific aptamers to the surface of reduced GO (RGO) coated Au films. The detection mechanism involves a detachment of α-thrombin-specific aptamers from the SPR biorecognition surface upon binding with α-thrombin, and leads to a noticeable change in the SPR resonant angle within a detection limit of 0.05 nM.

Indeed, as the surface of graphene may be decorated with NPs to amplify the SPP waves, this facilitates its applicability to SERS-based substrates for single molecule detection [93,96,112,113,118]. For instance, Liu et al. [119] have designed an AgNP functionalized GO for an ultrasensitive detection of aromatic molecules with various charges including, positively charged crystal violet (CV), negatively charged amaranth, and neutral phosphorus triphenyl (PPh3). This may be adapted for the determination of charged molecules including proteins and DNAs (phosphate backbone). Furthermore, Lu et al. [113] have established a SERS substrate based on an RGO film decorated with silver (Ag) NPs for the sensing of aromatic molecules. In comparison with graphene-only substrates, this AgNP-RGO composite shows a superior sensitivity, and a detection limit in the order of nM. Moreover, this may be harnessed to monitor the levels of aromatic residues namely, Amyloid-related proteins and short peptide fragments, which precede the formation of Amyloid fibrils in AD. An analogous setup for DNAs was tailored by He et al. [93] (Figure 1d), in which a multiplexed and sequence-specific detection was achieved. In particular, this involved a SERS-active substrate based on AuNP-decorated CVD-growth graphene. Due to the combination of AuNPs and graphene, the Raman signals of dye were electrochemically enhanced [120,121] by this novel substrate. With the AuNPs, DNA capture probes were assembled on the surface of graphene films. Consequently, it was reported that two different DNA targets sharing a substrate could be simultaneously determined (down to 10 pM) with a single light source.

2.3. Plasma-Processing: Graphene

The importance of plasma-treatment in graphene-based biosensors is three-fold, namely, to assist fabrication, enhance sensitivities, and enable the tailoring of functionalities, via rapid, scalable, versatile, and contaminant-free procedures (Figure 2). For instance, the synthesis of graphene via (H2/CH4) plasma-enabled chemical vapor deposition (PECVD) on Cu [122] or atmospheric pressured (CH4/H2/Ar) PECVD on SiO2 [123,124] present an energy efficient, high-quality yield and low temperature (~600 °C) alternative to the conventional methods such as thermal CVD (900–1000 °C) [125], thermal decomposition of SiC wafer [126], mechanical exfoliation of bi/tri-layer graphene [127,128], thermal annealing [129–131], and chemical [129,132,133] and photocatalytic [134,135] reduction from graphene oxide. On the other hand, surface functional groups of nanostructures created in a plasma environment are dependent on the active species and the specific plasma conditions. For example, high-pressure (e.g., at atmospheric pressure) plasmas features an environment with low ion collision frequencies, hence reducing damages on nanostructures induced by the highly energetic ions. By avoiding complex vacuum technologies, these high-pressure plasmas are also suitable for direct in-line surface modifications. In contrast, low-pressure plasmas are advantageous in providing a high uniform
and deep treatment to the nanostructures, due to the uniform processing environment with less ion collisions under the high vacuum.

Notably, the restoration of GO may be most efficiently achieved via plasma-treatment [123], as evidenced by the superior electrical conductivity of RGO and its structural characterization illustrated in Figure 2a–d. Flakes of GO (Figure 2a) were treated by H₂ plasma (10 mins at 525 °C), for the production of highly uniform reduced graphene oxide (RGO) sheets (Figure 2b). Correspondingly, the Raman spectra in Figure 2c demonstrates the quality and impact of plasma-assisted reduction of GO (i.e., “as-made”) to RGO. The plasma-assisted restoration of GO results in a decrease in \( I_D/I_G \) (D/G peak intensity) ratio from 1.03 (“as-made”) to 0.53 after 10 min of plasma exposure. As \( I_D/I_G \) is proportional to the average size of the \( sp^2 \) carbon domains, this decrease in \( I_D/I_G \) is attributed to the removal of defects and the conversion of \( sp^3 \) to \( sp^2 \) carbons. In Figure 2d, the C1 XPS spectra of GO after 10 min of plasma treatment further highlights the superior quality of graphene obtained via plasma-assisted reduction. In particular, a dominant C-C peak corresponds to the removal of most oxygen functional groups. This will not only amplify the sensitivities in graphene-based biosensors, but also provides a non-toxic and scalable substitute to typical hazardous wet chemical methods, such as hydrazine or sodium borohydride treatments, which may introduce significant impurities and defects.

**Figure 2.** Structures and morphologies of graphene oxide (GO) under plasma-assisted reduction and decoration with nanoparticles (NPs). Atomic force microscopy (AFM) characterization of (a) GO and (b) reduced graphene oxide (RGO) sheets after 10 min of H₂ plasma treatment at 525 °C; (c) The Raman spectra showing the quality and impact of plasma-assisted reduction of GO (i.e., “as-made”) to RGO; (d) The C1 XPS spectra of GO after 10 min of plasma treatment. Reproduced from [123]; (e) Transmission electron microscopy (TEM) image of nitrogen-doped graphene. Inset shows the selected-area electron diffraction (SAED). Reproduced from [136]; (f) High-resolution TEM image of GO nanosheets uniformly decorated with palladium (Pd)-NPs via a low temperature plasma-assisted fabrication. Reproduced from [137].
Moreover, plasma-treatment of graphene promotes the tailoring of functionalities for the realization of specific biorecognition domains. In particular, the controlled doping and oxidation of graphene outlines the two essential plasma-specific activations. Firstly, N\textsubscript{2} plasma may be utilized to simultaneously dope and reduce GO to a high quality \cite{136} (Figure 2e). Indeed, the doping of graphene enables the attachment of amino functional groups which facilitate the immobilisation of analyte-specific bioreceptors (e.g., antibodies, antigens, or ssDNAs) to enable specificity in biosensing. Moreover, as the photoluminescence of graphene may be enhanced upon oxidation with O\textsubscript{2} plasma, this presents an opportunity to fabricate highly-sensitive and selective platforms for FRET-based protein recognition by a faster, cheaper, and health-benign alternative of plasma-activation. This is important because chemically toxic treatments involving concentrated acids may induce significant substrate defects or unwanted impurities. Lastly, the plasma treatment may be utilized to produce GO-NP composites with a good dispersion of NPs (Figure 2f) \cite{137,138}.

3. Carbon Nanotubes

Carbon nanotubes (CNTs) are hollow graphitic nanomaterials comprised of cylindrical \textit{sp}^2-hybridized carbon atoms. CNTs exist in two principle forms, single-walled \textit{(i.e., SWCNT)} and multi-walled \textit{(i.e., MWCNT)}. The former is characterised by a one-dimensional tubular graphene sheet (1–2 nm diameter) \cite{139–141}, and the latter as concentric, closed graphite tubules, of diameter 2–50 nm with sub-nanometer (~0.35 nm) interlayer spacing \cite{142–144}. CNTs have many properties that are desired for biosensors, such as semiconducting characteristics, excellent electrical conductivity, high aspect ratio, mechanical integrity, and chemical stability. Consequently, CNTs have been integrated into numerous electrical \textit{(Section 3.1)} and optical \textit{(Section 3.2)} platforms, for the determination of biological complexes including, but not limited to, nucleic acids and protein biomarkers. In addition, due to the unique morphology of CNTs, three variants in biorecognition substrates, namely, single CNT platforms, randomly distributed CNT arrays, and vertically aligned CNT forests, have been realized.

3.1. CNT-Based Electrical Biosensors

The ability of CNTs to promote charge transfer has been a crucial aspect to its multiple successes in implementations towards electrical biosensors. CNT-based substrates with FET characteristics have been extensively investigated and tailored for protein sensing and DNA sequencing \cite{145–157}, as they
offer a highly-sensitive, label-free, and real-time detection. Typically, target analytes are detected by measuring a change in electrical conductivity across the CNT-FET channel caused by their binding with bioreceptors immobilized on the CNT surface. In FETs with horizontally aligned arrays of CNTs (Figure 3a), the detection of long or large biological complexes (e.g., DNAs, proteins) is challenged by a significant Debye screening beyond the CNT double layer. The strategies to overcome this problem have involved the use of small (few nm) receptors including, aptamers [151,158–160] and antibody-binding fragments [157,161], functionalized via NPs or chemical linkers with space-modifiers, on the walls of CNTs [153]. Yet another approach recently proposed by Oh et al. [145], involved the integration of CNTs to metal-semiconductor FETs (MESFETs). In particular, Oh et al. have designed a CNT-MESFET for a label-free, rapid, and highly sensitive (1 pg/mL) determination of Aβ in the human serum. A gold top gate was deposited on the middle of the CNT channel, where probe antibodies (protein A) were immobilized its surface. Subsequently, E. coli outer membranes were introduced to inhibit the non-specific binding of Aβ. The achieved 1 pg/mL detection limit not only presents a superior sensitivity to ELISAs for plasma Aβ, but also falls within the physiological range of Aβ in human serum.

Figure 3. Carbon nanotubes (CNT)-based biosensors including FETs, vertically aligned CNT arrays for SERS, CNTs for Raman tags, and fluorometric CNT arrays. (a) Schematic of an electrolyte-gated CNT-FET, in which CNT walls were noncovalently functionalized with porphyrin-based glycoconjugates. Reproduced from [162]; (b) Outline of the vertically aligned CNTs functionalization with AuNDs with an atmospheric pressured plasma jet (APPJ). Reproduced from [163]; (c) Multi-color SWCNT Raman labels for multiplexed protein detection; (d) Demonstration of the G-mode Raman scattering spectra of $^{12}$C (red) and $^{13}$C (green) SWCNT Raman tags. Reproduced from [164]; (e) A SWCNT/chitosan suspension was spotted on glass and functionalized with Ni-NTA to bind His-tag-containing capture proteins; (f) Illustration of the fluorescence change ($\Delta I/I_0$) following the immobilization of capture proteins and its subsequent binding with the analyte proteins on the SWCNT/chitosan array. Reproduced from [165].
3.2. CNT-Based Optical Biosensors

The electronic and structural properties of SWCNTs have been essential towards its successful integration in optical biosensors. In particular, the (i) excellent Raman scattering cross-section of SWCNTs, and (ii) its ability to enhance Raman signals near optical transition [166], in conjunction with (iii) its near-infrared (NIR) band-gap fluorescence (i.e., semiconducting SWCNTs) [167], have been exploited in the design of highly-sensitive and selective optical assays for protein biomarkers and DNA sequences. On one hand, this includes SERS-active [163,168–170] label-free platforms, and on the other, fluorometric assays [164,165,171,172] and CNT Raman labels [164] in multiplexed biorecognition assays. Notably, Yick et al. [163] have demonstrated a hybrid three-dimensional (3D) nanostructure of vertically aligned carbon nanotubes (VACNTs) for an effective microscopic area-selective sensing platform based on SERS (Figure 3b). An atmospheric-pressure microplasma jet (APPJ) was utilized to produce 3D microfluidic channels on the dense arrays of multi-walled VACNTs. Correspondingly, these plasma-treated (hydrophilic) channels were chemically functionalized with Au nanodots, through their ability to confine the Au nanodot aqueous solution. Moreover, these NDs may be adapted to function as preferential sites for the subsequent attachment and sensing of biomolecules (e.g., antibodies, antigens, DNAs, etc.) onto these hybrid structures limited to the plasma-modified VACNTs. Chen et al. [164] have realized a novel multiplexed protein detection array, in which macromolecular SWCNTs were functionalized as multicolor Raman labels. In particular, Raman detection benefits from the sharp scattering peaks of SWCNTs with minimal background interference, and thus provides a high signal-to-noise ratio for ultra-sensitive detection. In combination with SERS-active substrates, the strong Raman intensity of SWCNT tags enabled protein detection sensitivity to 1 fM. In this assay, SWNT Raman tags were utilized to detect human autoantibodies against [a] [b] [c] [d] [e] [f]
proteinase 3, a biomarker for the autoimmune Wegener’s granulomatosis disease. Various antibodies were conjugated to $^{12}$C and $^{13}$C SWCNT isotopes (Figure 3c,d), and a multiplexed two-color SWCNT Raman-based protein assay was established. In addition, Ahn et al. [165] have harnessed the fluorescence of SWCNTs to pioneer the first chemical approach for a selective and label-free microarray for single protein recognition (Figure 3e,f). In particular, hexahistidine-tagged capture proteins directly expressed by cell-free synthesis on a SWCNT/chitosan microarray were bound to a Ni$^{2+}$ chelated by Nα,Nα-bis(carboxymethyl)-L-lysine grafted to chitosan surrounding the SWCNT. The Ni$^{2+}$ functioned as a proximity quencher with the Ni$^{2+}$/SWCNT distance altered upon docking of the analyte proteins. This ability to discern single protein binding events decreased the detection limit from 100 nM, for the ensemble average, to 10 pM for an observation time of 600 s. More importantly, the versatility of cell-free synthesis to functionalize a nanosensor may be easily extended to include AD or PD biomarkers as capture proteins.

3.3. Plasma-Processing: CNTs

Plasma-processing of CNTs provides a practical and efficient tool for the independent control of surface temperature and surface passivation towards a deterministic control over nucleation, self-organisation and functionalization of the arrays of surface-supported CNTs [173,174]. Indeed, plasma-enabled CNT fabrication features remarkably lower temperatures (450 °C) [175–177], faster growth rates [178,179], denser growth patterns [180], and excellent morphological and structural features including superior defect-free SWCNTs, and a uniform distribution of CNT lengths and thickness across large patterns and arrays [180,181], as opposed to the conventional methods based on thermal CVD. The structures, morphologies, and the corresponding plasma-enabled growth mechanism for CNTs [180,182] are outlined in Figure 4. Figure 4a exemplifies a highly uniform and dense array of MWCNTs, grown by PECVD on nickel-coated glass. Acetylene gas was used as the carbon source, with ammonia gas for catalysis and dilution. Correspondingly, nanotubes with controllable diameters from 20 to 400 nanometers and lengths from 0.1 to 50 micrometers were obtained, with densities of $10^7$ CNTs/mm$^2$. In addition, these unique plasma-based treatments may be tailored to control the morphology of SWCNTs. In particular, Figure 4b illustrates a TEM of SWCNTs deposited on SiO$_2$ wafer/ Si substrate via PECVD (<750 °C) with fast heating, for the pyrolysis of pure C$_2$H$_2$ carbon source at low pressure (30 mTorr), in order to obtain a high yield of semiconducting SWCNTs.

Moreover, the incorporation of metal catalyst nanoparticles (CNPs), while essential for nucleation in the conventional thermal CVD synthesis of CNTs, remains detrimental for two primary reasons. Firstly, they impede direct integration into Si-dominated nanodevice platforms; and secondly, they contribute towards Ohmic losses in charge carrier transport along CNTs. Indeed, plasma processing in CNT growth addresses this concern at two fronts. Firstly, the direct integration of CNTs onto a Si nanodevice was enabled by high-density plasma treatment (CH$_4$/N$_2$ PECVD at 800 °C, high-vacuum $10^{-4}$ Pa) [183]. Secondly, plasma-enabled CNT growth demonstrates a catalyst-free synthesis of linear arrays of vertically aligned CNTs (VACNTs), with variable and graded morphologies and structures tailored by the plasma density [183,184].

Lastly, Figure 4d,e outline the growth of CNTs from CNP nucleation to termination, and the balance of carbon fluxes on surface-bound catalyst NPs/carbon nanostructures. In Figure 4e, the seven
The main stages of the formation of the carbon nanostructure patterns on the surface are highlighted. Sequentially, this involves the (1) nucleation of metal CNPs on the surface; (2) growth of metal CNPs on the substrate surface; (3) carbon supply to the surface, formation of carbon fluxes on the substrate surface between the CNPs, initial saturation of metal CNPs with carbon; (4) formation of carbon-saturated metal NPs; (5) nucleation of carbon nanostructures on the carbon saturated metal catalyst particles; (6) growth of nanostructures on the carbon-saturated metal CNPs due to carbon influx through Ni; and (7) vertical growth due to carbon influx through Ni and carbon removal due to sputtering.

Figure 4. Plasma-enabled growth of vertically aligned carbon nanotubes (CNTs), including CNT structures, morphologies, AuNP modification and growth mechanism. (a) MWCNTs fabricated on nickel-coated glass by PECVD. Reproduced from [185]; (b) TEM of SWCNTs deposited on SiO₂ wafer/Si substrate via PECVD (<750 °C) with fast heating. Reproduced from [186]; (c) Vertically aligned CNTs treated by cold atmospheric-pressure micro-plasma jet (APMPJ) for the decoration of AuNDs. Reproduced from [163]; (d) Overview of CNT growth from CNP nucleation to termination; (e) The seven main stages of the formation of the carbon nanostructure pattern on the surface. Reproduced from [30].

In general, plasmas can modify different nanostructures in a relatively homogeneous way and the stability of modified nanostructures can fulfill the real applications, provided that suitable plasma...
conditions are implemented. For example, the fabrication of an SERS-based protein sensing platform, namely, a dense structure of vertically aligned CNTs and 4-ATP functionalised AuNDs, was enabled by a rapid (10–30 s) cold atmospheric-pressure micro-plasma jet (APMPJ) treatment [163]. In contrast to the conventional low-pressure plasma systems, APMPJ operates at low (mW-W) power, room temperature and atmospheric pressure. Moreover, plasma-assisted CNT synthesis enables a narrower chirality distribution of SWCNTs, and a pronounced vertical alignment to the substrate. The former features a production of semiconducting SWCNTs in large fractions (96%) [186], as opposed to the conventional thermal CVD [187]. Furthermore, a controlled transition of SWCNTs from metallic to semiconducting via H2 plasma treatment [188] facilitates the operation of FET-based CNT protein biosensors. Additionally, the surface of CNTs may be activated with amino and carboxyl functional groups, to enable the immobilisation of probe biomolecules including, but not limited to, antibodies, antigens, and aptamers [160,189]. Notably, a low temperature (NH3 [190] or CF4 [191]) plasma-assisted activation of CNT surface demonstrates a superior and controlled functionalization, via an energy efficient, inexpensive, and significantly less destructive procedure as opposed to the hazardous chemical doping.

4. Carbon Nanowalls

Carbon nanowalls (CNWs), also known as vertically-oriented graphenes (VGs), are self-organised and open 3D inter-networked arrays of graphene nanosheets, with individual nanosheets composed of few-layered graphenes, of subnanometer interlayer spacings (0.34–0.37 nm) spanning several micrometers in lateral dimensions [192–195]. The unique morphology of CNWs presents a high density of (open) active graphitic edges and free active basal planes standing on a substrate. This is complemented by their exceptional tensile strength, high electrical conductivity, semiconducting nature, chemical stability, and ease of functionality [196].

4.1. CNW-Based Biosensors

The aforementioned unique features of CNWs have been harnessed in the design of FET devices [197] for immunosensing [198], electrochemical platforms for sequence-specific DNA detection [199,200], and novel absorbance [201] and plasmonic/SERS-active substrates [202,203] which may be tailored for the sensing of AD or PD biomarkers. For instance, Mao et al. [198] have developed a sensitive and selective FET biosensor with CNWs labeled with AuNP-antibody conjugates (Figure 5a). CNWs were directly grown on the sensor electrode via a single-step PECVD and functioned as a sensing channel. Subsequently, the protein detection was accomplished through the measurement of changes in the FET channel resistivity upon the antibody-antigen binding. Selectivity against immunoglobulin G (IgG), immunoglobulin M (IgM) and horse radish peroxide (HRP) was demonstrated at the ~2 ng/mL level. Moreover, this presents a single-step and reliable approach which may be adapted to prepare a label-free and real-time biosensing platform for AD or PD protein biomarkers. Arkhavan et al. [199] have fabricated a graphene oxide nanowall (GONW) electrode for a label-free and highly-sensitive (0.1 fM resolution) electrochemical detection towards the four bases of dsDNA and the SNPs of oligonucleotides. In particular, GONWs were electrophoretically deposited on a graphite electrode, and the oxidation signals of individual nucleotide bases were monitored by differential pulse voltammetry (DPV). Recently, Seo et al. [201] have pioneered (Ar/H2) plasma-grown VGs by
reforming natural honey precursors, which were subsequently decorated with AuNPs for Au-antibody sensing, whereby a SERS/SPR sensing platform may be facilitated by AuNPs (signal amplification) and shift in UV-Vis diffuse reflectance spectra. In particular, the N₂ plasma treatment of the VGs enabled the tuning of UV-Vis transmission in VGs for protein sensing (e.g., BSA immobilised on VGs) via Raman spectroscopy and UV-Vis spectrophotometry [202]. Lastly, Rider et al. [202] have established a 3D SERS/plasmonic sensing platform based on a plasma-enabled and catalyst-free synthesis of CNWs decorated with self-organized AuNPs (Figure 5b). The controllable high "bookshelf-like" surface coverage of the CNW basal plane by self-organized AuNP arrays was achieved through the use of weakly ionized plasma-based processes. Consequently, the Raman fingerprints corresponding to the radial breathing-modes of CNWs were significantly amplified due to the presence of Au NPs.

**Figure 5.** Carbon nanowalls (CNW)-based FET and plasmonic/SERS-active biosensing platforms. (a) A CNW substrate was decorated with AuNP-anti-IgG conjugates by electrodeposition, for the sensing of complementary IgGs. Reproduced from [198]; (b) CNWs synthesized on Si(100) substrate via a catalyst-free N₂ PECVD. The thermally evaporated AuNPs were self-assembled onto the CNWs as a SERS platform. Reproduced from [202].

### 4.2. Plasma-Processing: CNWs

First and foremost, plasma processing of CNWs provides a fast, single-step, energy-efficient and scalable fabrication with superior quality compared to VGs prepared via thermal CVD. In addition,
functionalizing CNWs through plasma-activation presents an eco-friendly and inexpensive procedure as opposed to hazardous wet-chemical methods which may introduce significant defects and impurities. Figure 6 illustrates the structures, morphologies and plasma-enabled growth mechanism of CNWs. In particular, CNW fabrication by PECVD via MW (CH\textsubscript{4}/H\textsubscript{2}), RF (CH\textsubscript{4}/Ar), electron beam excited (CH\textsubscript{4}/H\textsubscript{2}), helicon wave-excited (CH\textsubscript{4}), and DC (CH\textsubscript{4}/H\textsubscript{2}/Ar) plasmas [204–208], have demonstrated a catalyst-free, energy-efficient, and low-temperature (400–800 °C) alternative to non plasma-assisted methods including, sputtering (glassy carbon target) in CH\textsubscript{4}/Ar gas [209] and hot filament CVD in a CH\textsubscript{4}/H\textsubscript{2} or CH\textsubscript{4}/He background gas [210–212], which primarily utilize expensive purified hydrocarbon gases in high-temperature environments (700–1000 °C) while involving long fabrication times (20–45 min). Furthermore, recent advances in CNW synthesis has established a single-step, fast, scalable and environmentally-benign (Ar/H\textsubscript{2} RF) plasma-enabled CNW growth from natural precursors, demonstrating good VG-substrate adhesion and controllability over the degree of graphitization and density of VG edge planes [213,214].

**Figure 6.** Structures, morphologies, and growth mechanism for plasma-enabled catalyst-free growth of few-layer CNWs. (a) High-resolution SEM of ultra-thin CNWs produced from natural honey; (b) high-resolution TEM image of the graphitic edges of CNWs. Reproduced from [201]; (c) CNWs with self-organised AuNP arrays; (d) high-resolution TEM image of 4-layer VGs. Reproduced from [202]; (e) AuNPs introduced into CNWs by electrodeposition. Reproduced from [198]; (f) growth model for CNWs. Reproduced from [215].
5. Conclusions and Outlook

The excellent inherent electrical, optical, and structural properties of CNs render them essential for implementation in biosensors and bioassays. In addition, the sensing of biomarkers indicative of presymptomatic NDs (e.g., AD or PD) requires a biorecognition platform with unprecedented specificity and sensitivity in complex biological fluids such as blood and CSF directly. Moreover, a reproducible, inexpensive and resource-efficient device fabrication is necessary in order to develop a practical biosensor. To this end, we suggest an electrochemical CNW-based substrate to be the most viable platform for the detection of AD or PD biomarkers. CNWs can be directly grown on various conductive substrates so as to reduce the fabrication steps and cost associated with the production of the sensing systems. At present, while only a handful of CNWs-based biosensors for metabolites, proteins and DNAs have been developed, they have consistently demonstrated comparable or improved sensitivities, selectivities, dynamical ranges, and fabrication costs, as compared to biosensors made of CNTs and graphene (see Table 1). In particular, the ease of electrode fabrication, coupled with the inherent properties of graphene, reactive open edges and high NP loading capacity of CNWs, may facilitate a highly sensitive, selective and rapid biosensing device. Consequently, an electrochemical sensor based on CNWs decorated with probe-functionalized (e.g., complementary antibody, fragments, or ssDNA) NPs may provide the most effective approach for a selective determination of CSF protein biomarkers, and a sequence-specific detection of DNA biomarkers. In addition, probe biomolecules may be customized to capture the neurotoxic Aβ42 oligomeric species while in human CSF [216], target specific regions of Aβ for the differentiation between various oligomers [29] and conformers [217,218], or be replaced with phospholipid-specific biomolecules [219], for the detection of blood-based phospholipid biomarkers. Alternatively, Aβ-specific ligands may be employed as bioreceptors ([220] and references therein) to reduce the fabrication costs associated with antibody or antigen probes.

Moreover, plasma-based techniques for fabrication and surface treatment may be implemented to most effectively enable, enhance, and tailor the device performance and optimize the fabrication processes of CNs towards the construction of biosensing devices with superior properties, via a plethora of energy-efficient, environmentally-benign, and inexpensive approaches, for future healthcare applications. In particular, by harnessing these unique and beneficial plasma-based techniques for the surface modification of CNWs, this highlights a great promise towards the fabrication of an ultrasensitive, ultraselective, and cost-efficient biosensor, for an early diagnosis of NDs. More specifically, these plasma-based approaches offer a highly effective and efficient functionalization of CNs. Consequently, this promotes a facile immobilization of highly specific probe biomolecules (e.g., antibodies, antigens, aptamers, and other selective receptors), and hence, may enable a highly versatile and selective biorecognition device capable of detecting ND biomarkers in complex biological fluids such as blood and CSF. Furthermore, these sensing strategies may be tailored to facilitate a range of highly promising therapeutics for the prevention and treatment of NDs. For example, this may involve the inhibition of biomolecules such as mRNA [221], β secretase [222], and interleukin-12/23 [223], whose expressions are crucial in the early stages of ND pathogenesis. However, further research in the biocompatibility of CNs remains highly warranted [224]. Notably, the integration of plasma-enabled CNs in the next-generation of biosensors presents a promising solution for the realization of devices, which may be tailored for the early diagnosis of a diverse spectrum of
life-threatening diseases (e.g., diabetes, cancer, and cardiovascular diseases) in addition to the neurodegenerative diseases.

**Table 1.** A survey of CN-based biosensors that have been realized for the detection of metabolism-related biomolecules, DNAs and proteins. These biosensors have been selected to illustrate the varying specificity, sensitivity and fabrication approaches for various CN substrates (*i.e.*, CNWs, CNTs or graphene), biomolecules of interest, and transduction mechanisms.

| Sensors                     | Target analyte | Detection limit | Detection range | Reference |
|-----------------------------|----------------|-----------------|-----------------|-----------|
| CNWs on graphite electrode | DNAs           | 9.4 zM          | 0.1 fM–10 mM    | [199]     |
| GO with sulfonated polyaniline | DNAs         | 5.2 fM          | 0.1 µM–10 fM    | [225]     |
| CNWs on Si                  | Metabolites    | 0.17 µM         | 1–100 µM        | [226]     |
| CNWs on Ti-coated Si        | Metabolites    | 0.3 µM          | 0.01–50 mM      | [227]     |
| CNWs on Au                  | Immunoglobulins| 2 ng/mL         | 2–20 ng/mL      | [198]     |
| CNTs                        | DNAs           | 100 aM          | 100 aM–1 pM     | [228]     |
| CNT-based FETs              | DNAs           | 0.1 mg/mL       | –               | [229]     |
| Nitrogen-doped MWCNTs       | Glucose        | 10 µM           | 0.02–1.02 mM    | [230]     |
| MWCNTs with GOx and Au NPs | Glucose        | 20 µM           | 0.05–22 mM      | [231]     |
| SWCNTs on SiO₂              | Immunoglobulins| 1 pg/mL         | 100 fg/mL–1000 pg/mL | [157]   |
| SWCNTs on SiO₂              | Immunoglobulins| 1 pg/mL         | 1–1000 pg/mL    | [145]     |
| Functionalized SWCNTS       | Immunoglobulins| 1 fM             | 100 pM–1 fM     | [164]     |
| Graphene                    | DNAs           | 0.12 pM         | 1 pM–0.1 µM     | [232]     |
| Graphene on SiO₂            | DNAs           | 10 pM           | 10 pM–100 nM    | [93]      |
| N-doped graphene oxide      | Immunoglobulins| 0.012 U/mL      | 0.1–20 U/mL     | [75]      |
| Graphene oxide with Au NPs | Immunoglobulins| 1 pM             | 1 pM–1 µM       | [70]      |
| Graphene oxide with Au NPs | Immunoglobulins| 0.0375 µg/mL    | 0.0375–40 µg/mL | [110]     |

**Acknowledgments**

Shafique Pineda acknowledges the Australian Postgraduate Award scholarship and the CSIRO’s OCE postgraduate top-up scholarship. Zhao Jun Han and Kostya (Ken) Ostrikov acknowledge the DECRA and Future fellowships, respectively, from the Australian Research Council (ARC). This work is partially supported by the ARC and CSIRO’s OCE Science Leadership Program.

**Conflicts of Interest**

The authors declare no conflict of interest.

**References**

1. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schiffer, G.; Siderowf, A.; *et al*. Projected number of people with parkinson disease in the most populous nations, 2005 through 2030. *Neurology* 2007, 68, 384–386.

2. Prince, M.; Bryce, R.; Albanese, E.; Wimo, A.; Ribeiro, W.; Ferri, C.P. The global prevalence of dementia: A systematic review and metaanalysis. *Alzheimer’s Dement.* 2013, 9, 63–75.e2.
3. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.Q.; et al. Global prevalence of dementia: A delphi consensus study. Lancet 2005, 366, 2112–2117.

4. Brookmeyer, R.; Gray, S.; Kawas, C. Projections of alzheimer’s disease in the united states and the public health impact of delaying disease onset. Am. J. Public Health 1998, 88, 1337–1342.

5. Abbott, A. Dementia: A problem for our age. Nature 2011, 475, S2–S4.

6. Rapoport, S.I. In vivo pet imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in alzheimer’s disease. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249, 46–55.

7. Ikonomovic, M.D.; Klunk, W.E.; Abrahamson, E.E.; Mathis, C.A.; Price, J.C.; Tsopelas, N.D.; Lopresti, B.J.; Ziolkto, S.; Bi, W.Z.; Paljug, W.R.; et al. Post-mortem correlates of in vivo pib-pet amyloid imaging in a typical case of alzheimer’s disease. Brain 2008, 131, 1630–1645.

8. Kung, M.P.; Hou, C.; Zhuang, Z.P.; Skovronsky, D.; Kung, H.F. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with alzheimer’s disease. Brain Res. 2005, 1031, 302.

9. Darvesh, S.; Walsh, R.; Kumar, R.; Caines, A.; Roberts, S.; Magee, D.; Rockwood, K.; Martin, E. Inhibition of human cholinesterases by drugs used to treat alzheimer disease. Alzheimer Dis. Assoc. Dis. 2003, 17, 117–126.

10. Rössler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stahelin, H.B.; Hartman, R.; Gharabawi, M. Efficacy and safety of rivastigmine in patients with alzheimer’s disease: International randomised controlled trial. BMJ 1999, 318, 633–638.

11. Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, D.W.; Pfeiffer, E.; et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for alzheimer’s disease. N. Engl. J. Med. 1997, 336, 1216–1222.

12. Factor, S.A.; Molho, E.S.; Feustel, P.J.; Brown, D.L.; Evans, S.M. Long-term comparative experience with tolcapone and entacapone in advanced parkinson’s disease. Clin. Neuropharmacol. 2001, 24, 295–299.

13. Holloway, R.G.; Shoulson, I.; Kieburtz, K.; McDermott, M.; Shinaman, A.; Kamp, C.; Fahn, S.; Lang, A.; Marek, K.; Seibyl, J.; et al. Pramipexole vs levodopa as initial treatment for parkinson disease—A 4-year randomized controlled trial. Arch. Neurol. (Chicago) 2004, 61, 1044–1053.

14. Rascol, O.; Goetz, C.; Koller, W.; Poewe, W.; Sampaio, C. Treatment interventions for parkinson’s disease: An evidence based assessment. Lancet 2002, 359, 1589–1598.

15. Querfurth, H.W.; LaFerla, F.M. Alzheimer’s disease. N. Engl. J. Med. 2010, 362, 329–344.

16. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in alzheimer disease. Nat. Rev. Neuroil. 2010, 6, 131–144.

17. Chung, K.K.; Zhang, Y.; Lim, K.L.; Tanaka, Y.; Huang, H.; Gao, J.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for lewy-body formation in parkinson disease. Nat. Med. 2001, 7, 1144–1150.

18. Lang, A.E.; Lozano, A.M. Parkinson’s disease. N. Engl. J. Med. 1998, 339, 1044–1053.

19. Kingswell, K. Alzheimer disease: Csf levels of mitochondrial DNA—A new biomarker for preclinical alzheimer disease? Nat. Rev. Neuroil. 2013, 9, 420, doi:10.1038/nrneurol.2013.134.
20. Mapstone, M.; Cheema, A.K.; Fiandaca, M.S.; Zhong, X.; Mhyre, T.R.; Macarthur, L.H.; Hall, W.J.; Fisher, S.G.; Peterson, D.R.; Haley, J.M.; et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20, 415–418.

21. Ammar, M.; Smadja, C.; Giang Thi Phuong, L.; Azzouz, M.; Vigneron, J.; Etcheberry, A.; Taverna, M.; Dufour-Gergam, E. A new controlled concept of immune-sensing platform for specific detection of alzheimer’s biomarkers. Biosens. Bioelectron. 2013, 40, 329–335.

22. Chikae, M.; Fukuda, T.; Kerman, K.; Idegami, K.; Miura, Y.; Tamiya, E. Amyloid-beta detection with saccharide immobilized gold nanoparticle on carbon electrode. Bioelectrochemistry 2008, 74, 118–123.

23. Li, H.; Cao, Y.; Wu, X.; Ye, Z.; Li, G. Peptide-based electrochemical biosensor for amyloid beta 1–42 soluble oligomer assay. Talanta 2012, 93, 358–363.

24. Prabhulkar, S.; Piatyszek, R.; Cirrito, J.R.; Wu, Z.Z.; Li, C.Z. Microbiosensor for alzheimer’s disease diagnostics: Detection of amyloid beta biomarkers. J. Neurochem. 2012, 122, 374–381.

25. Rushworth, J.V.; Ahmed, A.; Griffiths, H.H.; Pollock, N.M.; Hooper, N.M.; Millner, P.A. A label-free electrical impedimetric biosensor for the specific detection of alzheimer’s amyloid-beta oligomers. Biosens. Bioelectron. 2013, 56C, 83–90.

26. Sierks, M.R.; Chatterjee, G.; McGraw, C.; Kasturirangan, S.; Schulz, P.; Prasad, S. CsF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr. Biol. (UK) 2011, 3, 1188–1196.

27. Chou, I.H.; Benford, M.; Beier, H.T.; Cote, G.L.; Wang, M.; Jing, N.; Kameoka, J.; Good, T.A. Nanofluidic biosensing for beta-amyloid detection using surface enhanced raman spectroscopy. Nano Lett. 2008, 8, 1729–1735.

28. Gheorghiu, M.; David, S.; Polonschii, C.; Olaru, A.; Gaspar, S.; Bajenaru, O.; Popescu, B.O.; Gheorghiu, E. Label free sensing platform for amyloid fibrils effect on living cells. Biosens. Bioelectron. 2014, 52, 89–97.

29. Stravalaci, M.; Bastone, A.; Beeg, M.; Cagnotto, A.; Colombo, L.; di Fede, G.; Tagliavini, F.; Cantu, L.; del Favero, E.; Mazzanti, M.; et al. Specific recognition of biologically active amyloid-beta oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in caenorhabditis elegans. J. Biol. Chem. 2012, 287, 27796–27805.

30. Ostrikov, K.; Neyts, E.C.; Meyyappan, M. Plasma nanoscience: From nano-solids in plasmas to nano-plasmas in solids. Adv. Phys. 2013, 62, 113–224.

31. Azarenkov, N.A.; Denisenko, I.B.; Ostrikov, K.N. A model of a large-area planar plasma producer based on surface wave propagation in a plasma-metal structure with a dielectric sheath. J. Phys. D Appl. Phys. 1995, 28, 2465–2469.

32. Mariotti, D.; Ostrikov, K. Tailoring microplasma nanofabrication: From nanostructures to nanoarchitectures. J. Phys. D Appl. Phys. 2009, 42, doi:10.1088/0022-3727/42/9/092002.

33. Ostrikov, K.N.; Yu, M.Y.; Sugai, H. Standing surface waves in a dust-contaminated large-area planar plasma source. J. Appl. Phys. 1999, 86, 2425–2430.

34. Geim, A.K.; Novoselov, K.S. The rise of graphene. Nat. Mater. 2007, 6, 183–191.

35. Novoselov, K.S.; Geim, A.K.; Morozov, S.V.; Jiang, D.; Zhang, Y.; Dubonos, S.V.; Grigorieva, I.V.; Firsov, A.A. Electric field effect in atomically thin carbon films. Science 2004, 306, 666–669.
36. Allen, M.J.; Tung, V.C.; Kaner, R.B. Honeycomb carbon: A review of graphene. Chem. Rev. 2010, 110, 132–145.
37. Lee, C.; Wei, X.; Kysar, J.W.; Hone, J. Measurement of the elastic properties and intrinsic strength of monolayer graphene. Science 2008, 321, 385–388.
38. Zhu, Y.; Murali, S.; Cai, W.; Li, X.; Suk, J.W.; Potts, J.R.; Ruoff, R.S. Graphene-based materials: Graphene and graphene oxide: Synthesis, properties, and applications. Adv. Mater. 2010, 22, 3906–3924.
39. Stoller, M.D.; Park, S.; Zhu, Y.; An, J.; Ruoff, R.S. Graphene-based ultracapacitors. Nano Lett. 2008, 8, 3498–3502.
40. Park, S.; Ruoff, R.S. Chemical methods for the production of graphenes. Nat. Nano 2009, 4, 217–224.
41. Georgakilas, V.; Otyepka, M.; Bourlinos, A.B.; Chandra, V.; Kim, N.; Kemp, K.C.; Hobza, P.; Zboril, R.; Kim, K.S. Functionalization of graphene: Covalent and non-covalent approaches, derivatives and applications. Chem. Rev. 2012, 112, 6156–6214.
42. Huang, X.; Qi, X.; Boey, F.; Zhang, H. Graphene-based composites. Chem. Soc. Rev. 2012, 41, 666–686.
43. Tang, Y.B.; Yin, L.C.; Yang, Y.; Bo, X.H.; Cao, Y.L.; Wang, H.E.; Zhang, W.J.; Bello, I.; Lee, S.T.; Cheng, H.M.; et al. Tunable band gaps and p-type transport properties of boron-doped graphenones by controllable ion doping using reactive microwave plasma. ACS Nano 2012, 6, 1970–1978.
44. Park, C.S.; Zhao, Y.; Lee, J.H.; Whang, D.; Shon, Y.; Song, Y.H.; Lee, C.J. Tunable bandgap of a single layer graphene doped by the manganese oxide using the electrochemical doping. Appl. Phys. Lett. 2013, 102, 032106.
45. Matis, B.R.; Burgess, J.S.; Bulat, F.A.; Friedman, A.L.; Houston, B.H.; Baldwin, J.W. Surface doping and band gap tunability in hydrogenated graphene. ACS Nano 2012, 6, 17–22.
46. Novoselov, K.S.; Geim, A.K.; Morozov, S.V.; Jiang, D.; Katsnelson, M.I.; Grigorieva, I.V.; Dubonos, S.V.; Firsov, A.A. Two-dimensional gas of massless dirac fermions in graphene. Nature 2005, 438, 197–200.
47. Berger, C.; Song, Z.M.; Li, X.B.; Wu, X.S.; Brown, N.; Naud, C.; Mayou, D.; Li, T.B.; Hass, J.; Marchenkov, A.N.; et al. Electronic confinement and coherence in patterned epitaxial graphene. Science 2006, 312, 1191–1196.
48. Li, G.; Andrei, E.Y. Observation of landau levels of dirac fermions in graphite. Nat. Phys. 2007, 3, 623–627.
49. Zhou, S.Y.; Gweon, G.H.; Graf, J.; Fedorov, A.V.; Spataru, C.D.; Diehl, R.D.; Kopelevich, Y.; Lee, D.H.; Louie, S.G.; Lanzara, A. First direct observation of dirac fermions in graphite. Nat. Phys. 2006, 2, 595–599.
50. Zhang, Y.; Tan, Y.-W.; Stormer, H.L.; Kim, P. Experimental observation of the quantum hall effect and berry’s phase in graphene. Nature 2005, 438, 201–204.
51. Mohanty, N.; Berry, V. Graphene-based single-bacterium resolution biodevice and DNA transistor: Interfacing graphene derivatives with nanoscale and microscale biocomponents. Nano Lett. 2008, 8, 4469–4476.
52. Baraket, M.; Stine, R.; Lee, W.K.; Robinson, J.T.; Tamanaha, C.R.; Sheehan, P.E.; Walton, S.G. Aminated graphene for DNA attachment produced via plasma functionalization. *Appl. Phys. Lett.* 2012, 100, 233123.

53. Guo, S.R.; Lin, J.; Penchev, M.; Yengel, E.; Ghazinejad, M.; Ozkan, C.S.; Ozkan, M. Label free DNA detection using large area graphene based field effect transistor biosensors. *J. Nanosci. Nanotechnol.* 2011, 11, 5258–5263.

54. Stine, R.; Robinson, J.T.; Sheehan, P.E.; Tamanaha, C.R. Real-time DNA detection using reduced graphene oxide field effect transistors. *Adv. Mater.* 2010, 22, 5297–5300.

55. Hummers, W.S.; Offeman, R.E. Preparation of graphitic oxide. *J. Am. Chem. Soc.* 1958, 80, 1339–1339.

56. Gilje, S.; Han, S.; Wang, M.; Wang, K.L.; Kaner, R.B. A chemical route to graphene for device applications. *Nano Lett.* 2007, 7, 3394–3398.

57. Park, S.; Lee, K.S.; Bozoklu, G.; Cai, W.; Nguyen, S.T.; Ruoff, R.S. Graphene oxide papers modified by divalent ions-enhancing mechanical properties via chemical cross-linking. *ACS Nano* 2008, 2, 572–578.

58. Yin, Z.Y.; He, Q.Y.; Huang, X.; Zhang, J.; Wu, S.X.; Chen, P.; Lu, G.; Chen, P.; Zhang, Q.C.; Yan, Q.Y.; et al. Real-time DNA detection using pt nanoparticle-decorated reduced graphene oxide field-effect transistors. *Nanoscale* 2012, 4, 293–297.

59. Dong, X.C.; Shi, Y.M.; Huang, W.; Chen, P.; Li, L.J. Electrical detection of DNA hybridization with single-base specificity using transistors based on CVD-grown graphene sheets. *Adv. Mater.* 2010, 22, 1649–1653.

60. Chen, T.Y.; Phan, T.K.L.; Hsu, C.L.; Lee, Y.H.; Wang, J.T.W.; Wei, K.H.; Lin, C.T.; Li, L.J. Label-free detection of DNA hybridization using transistors based on cvd grown graphene. *Biosens. Bioelectron.* 2013, 41, 103–109.

61. Cai, B.; Wang, S.; Huang, L.; Ning, Y.; Zhang, Z.; Zhang, G.-J. Ultrasensitive label-free detection of pna-DNA hybridization by reduced graphene oxide field-effect transistor biosensor. *ACS Nano* 2014, 8, 2632–2638.

62. Kim, D.J.; Sohn, I.Y.; Jung, J.H.; Yoon, O.J.; Lee, N.E.; Park, J.S. Reduced graphene oxide field-effect transistor for label-free femtomolar protein detection. *Biosens. Bioelectron.* 2013, 41, 621–626.

63. Mao, S.; Lu, G.H.; Yu, K.H.; Bo, Z.; Chen, J.H. Specific protein detection using thermally reduced graphene oxide sheet decorated with gold nanoparticle-antibody conjugates. *Adv. Mater.* 2010, 22, 3521–3526.

64. Mao, S.; Yu, K.H.; Lu, G.H.; Chen, J.H. Highly sensitive protein sensor based on thermally-reduced graphene oxide field-effect transistor. *Nano Res.* 2011, 4, 921–930.

65. Kurkina, T.; Sundaram, S.; Sundaram, R.S.; Re, F.; Masserini, M.; Kern, K.; Balasubramanian, K. Self-assembled electrical biodetector based on reduced graphene oxide. *ACS Nano* 2012, 6, 5514–5520.

66. Sharon, E.; Liu, X.Q.; Freeman, R.; Yehezkeli, O.; Willner, I. Label-free analysis of thrombin or Hg$^{2+}$ ions by nucleic acid-functionalized graphene oxide matrices assembled on field-effect transistors. *Electroanalysis* 2013, 25, 851–856.
67. Saltzgaber, G.; Wojcik, P.; Sharf, T.; Leyden, M.R.; Wardini, J.L.; Heist, C.A.; Adenuga, A.A.; Remcho, V.T.; Minot, E.D. Scalable graphene field-effect sensors for specific protein detection. *Nanotechnology* **2013**, *24*, 355502.

68. Kim, D.J.; Park, H.C.; Sohn, I.Y.; Jung, J.H.; Yoon, O.J.; Park, J.S.; Yoon, M.Y.; Lee, N.E. Electrical graphene aptasensor for ultra-sensitive detection of anthrax toxin with amplified signal transduction. *Small* **2013**, *9*, 3352–3360.

69. Ohno, Y.; Maehashi, K.; Matsumoto, K. Label-free biosensors based on aptamer-modified graphene field-effect transistors. *J. Am. Chem. Soc.* **2010**, *132*, 18012–18013.

70. Myung, S.; Solanki, A.; Kim, C.; Park, J.; Kim, K.S.; Lee, K.B. Graphene-encapsulated nanoparticle-based biosensor for the selective detection of cancer biomarkers. *Adv. Mater.* **2011**, *23*, 2221–2225.

71. Johnsson, B.; Lofas, S.; Lindquist, G. Immobilization of proteins to a carboxymethyl-dextran-modified gold surface for biospecific interaction analysis in surface-plasmon resonance sensors. *Anal. Biochem.* **1991**, *198*, 268–277.

72. Turkova, J. Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function. *J. Chromatogr. B* **1999**, *722*, 11–31.

73. Cazzaniga, E.; Bulbarelli, A.; Lonati, E.; Orlando, A.; Re, F.; Gregori, M.; Masserini, M. Abeta peptide toxicity is reduced after treatments decreasing phosphatidyethanolamine content in differentiated neuroblastoma cells. *Neurochem. Res.* **2011**, *36*, 863–869.

74. Mao, K.X.; Wu, D.; Li, Y.; Ma, H.M.; Ni, Z.Z.; Yu, H.Q.; Luo, C.N.; Wei, Q.; Du, B. Label-free electrochemical immunosensor based on graphene/methylene blue nanocomposite. *Anal. Biochem.* **2012**, *422*, 22–27.

75. Li, H.; He, J.; Li, S.; Turner, A.P. Electrochemical immunosensor with n-doped graphene-modified electrode for label-free detection of the breast cancer biomarker CA 15-3. *Biosens. Bioelectron.* **2013**, *23*, 25–29.

76. Li, B.Y.; Shi, X.H.; Gu, W.; Zhao, K.; Chen, N.N.; Xian, Y.Z. Graphene based electrochemical biosensor for label-free measurement of the activity and inhibition of protein tyrosine kinase. *Analyst* **2013**, *138*, 7212–7217.

77. Liu, J.; Lu, C.Y.; Zhou, H.; Xu, J.J.; Wang, Z.H.; Chen, H.Y. A dual-functional electrochemical biosensor for the detection of prostate specific antigen and telomerase activity. *Chem. Commun.* **2013**, *49*, 6602–6604.

78. Huang, K.J.; Niu, D.J.; Sun, J.Y.; Han, C.H.; Wu, Z.W.; Li, Y.L.; Xiong, X.Q. Novel electrochemical sensor based on functionalized graphene for simultaneous determination of adenine and guanine in DNA. *Colloid Surface B* **2011**, *82*, 543–549.

79. Goh, M.S.; Pumera, M. Oxidation of DNA bases influenced by the presence of other bases. *Electroanalysis* **2012**, *24*, 1147–1152.

80. Du, M.; Yang, T.; Jiao, K. Immobilization-free direct electrochemical detection for DNA specific sequences based on electrochemically converted gold nanoparticles/graphene composite film. *J. Mater. Chem.* **2010**, *20*, 9253–9260.

81. Li, D.; Song, S.P.; Fan, C.H. Target-responsive structural switching for nucleic acid-based sensors. *Accounts Chem. Res.* **2010**, *43*, 631–641.
82. Bo, Y.; Wang, W.Q.; Qi, J.F.; Huang, S.S. A DNA biosensor based on graphene paste electrode modified with prussian blue and chitosan. *Analyst* 2011, 136, 1946–1951.

83. Guo, S.J.; Du, Y.; Yang, X.; Dong, S.J.; Wang, E.K. Solid-state label-free integrated aptasensor based on graphene-mesoporous silica-gold nanoparticle hybrids and silver microspheres. *Anal. Chem.* 2011, 83, 8035–8040.

84. Lin, L.; Liu, Y.; Tang, L.H.; Li, J.H. Electrochemical DNA sensor by the assembly of graphene and DNA-conjugated gold nanoparticles with silver enhancement strategy. *Analyst* 2011, 136, 4732–4737.

85. Qiu, Y.Y.; Qu, X.J.; Dong, J.; Ai, S.Y.; Han, R.X. Electrochemical detection of DNA damage induced by acrylamide and its metabolite at the graphene-ionic liquid-nafion modified pyrolytic graphite electrode. *J. Hazard. Mater.* 2011, 190, 480–485.

86. Zhao, J.; Chen, G.F.; Zhu, L.; Li, G.X. Graphene quantum dots-based platform for the fabrication of electrochemical biosensors. *Electrochem. Commun.* 2011, 13, 31–33.

87. Qi, X.W.; Gao, H.W.; Zhang, Y.Y.; Wang, X.Z.; Chen, Y.; Sun, W. Electrochemical DNA biosensor with chitosan-CosO₄ nanorod-graphene composite for the sensitive detection of staphylococcus aureus nuc gene sequence. *Bioelectrochemistry* 2012, 88, 42–47.

88. Gupta, V.K.; Yola, M.L.; Qureshi, M.S.; Solak, A.O.; Atar, N.; Ustundag, Z. A novel impedimetric biosensor based on graphene oxide/gold nanoplatelet platform for detection of DNA arrays. *Sens. Actuators B Chem.* 2013, 188, 1201–1211.

89. Zhang, Y.Z.; Jiang, W. Decorating graphene sheets with gold nanoparticles for the detection of sequence-specific DNA. *Electrochim. Acta* 2012, 71, 239–245.

90. Bonanni, A.; Pumera, M. Graphene platform for hairpin-DNA-based impedimetric genosensing. *ACS Nano* 2011, 5, 2356–2361.

91. Loo, A.H.; Bonanni, A.; Pumera, M. Thrombin aptasensing with inherently electroactive graphene oxide nanoplatelets as labels. *Nanoscale* 2013, 5, 4758–4762.

92. Zhang, C.L.; Xu, J.; Zhang, S.M.; Ji, X.H.; He, Z.K. One-pot synthesized DNA-cdte quantum dots applied in a biosensor for the detection of sequence-specific oligonucleotides. *Chem. Eur. J.* 2012, 18, 8296–8300.

93. He, S.J.; Liu, K.K.; Su, S.; Yan, J.; Mao, X.H.; Wang, D.F.; He, Y.; Li, L.J.; Song, S.P.; Fan, C.H. Graphene-based high-efficiency surface-enhanced raman scattering-active platform for sensitive and multiplex DNA detection. *Anal. Chem.* 2012, 84, 4622–4627.

94. Bonanni, A.; Chua, C.K.; Pumera, M. Rational design of carboxyl groups perpendicularly attached to a graphene sheet: A platform for enhanced biosensing applications. *Chemistry* 2014, 20, 217–222.

95. Han, X.W.; Fang, X.; Shi, A.Q.; Wang, J.; Zhang, Y.Z. An electrochemical DNA biosensor based on gold nanorods decorated graphene oxide sheets for sensing platform. *Anal. Biochem.* 2013, 443, 117–123.

96. Wu, Y.M.; Xu, W.J.; Bai, L.J.; Yuan, Y.L.; Yi, H.Y.; Chai, Y.Q.; Yuan, R. Ultrasensitive thrombin detection based on direct electrochemistry of highly loaded hemoglobin spheres-encapsulated platinum nanoparticles as labels and electrocatalysts. *Biosens. Bioelectron.* 2013, 50, 50–56.
97. Zhao, J.; Liu, M.L.; Zhang, Y.Y.; Li, H.T.; Lin, Y.H.; Yao, S.Z. Apoferritin protein nanoparticles dually labeled with aptamer and horseradish peroxidase as a sensing probe for thrombin detection. *Anal. Chim. Acta* 2013, 759, 53–60.

98. Grigorenko, A.N.; Polini, M.; Novoselov, K.S. Graphene plasmonics. *Nat. Photon.* 2012, 6, 749–758.

99. Xu, W.; Mao, N.; Zhang, J. Graphene: A platform for surface-enhanced raman spectroscopy. *Small* 2013, 9, 1206–1224.

100. Swathi, R.S.; Sebastian, K.L. Distance dependence of fluorescence resonance energy transfer. *J. Chem. Sci.* 2009, 121, 777–787.

101. Swathi, R.S.; Sebastian, K.L. Long range resonance energy transfer from a dye molecule to graphene has (distance)$^{-4}$ dependence. *J. Chem. Phys.* 2009, 130, doi:10.1063/1.3077292.

102. Swathi, R.S.; Sebastian, K.L. Resonance energy transfer from a dye molecule to graphene. *J. Chem. Phys.* 2008, 129, doi:10.1063/1.2956498.

103. Li, X.; Ma, K.; Zhu, S.J.; Yao, S.Y.; Liu, Z.Y.; Xu, B.; Yang, B.; Tian, W.J. Fluorescent aptasensor based on aggregation-induced emission probe and graphene oxide. *Anal. Chem.* 2014, 86, 298–303.

104. Dong, H.; Gao, W.; Yan, F.; Ji, H.; Ju, H. Fluorescence resonance energy transfer between quantum dots and graphene oxide for sensing biomolecules. *Anal. Chem.* 2010, 82, 5511–5517.

105. Chang, H.; Tang, L.; Wang, Y.; Jiang, J.; Li, J. Graphene fluorescence resonance energy transfer aptasensor for the thrombin detection. *Anal. Chem.* 2010, 82, 2341–2346.

106. Jung, J.H.; Cheon, D.S.; Liu, F.; Lee, K.B.; Seo, T.S. A graphene oxide based immuno-biosensor for pathogen detection. *Angew. Chem. Int. Edit.* 2010, 49, 5708–5711.

107. Liu, F.; Choi, J.Y.; Seo, T.S. Graphene oxide arrays for detecting specific DNA hybridization by fluorescence resonance energy transfer. *Biosens. Bioelectron.* 2010, 25, 2361–2365.

108. Wang, L.; Zhu, C.; Han, L.; Jin, L.; Zhou, M.; Dong, S. Label-free, regenerative and sensitive surface plasmon resonance and electrochemical aptasensors based on graphene. *Chem. Commun.* 2011, 47, 7794–7796.

109. Zhang, J.; Sun, Y.; Wu, Q.; Zhang, H.; Bai, Y.; Song, D. A protein a modified Au-graphene oxide composite as an enhanced sensing platform for SPR-based immunoassay. *Analyst* 2013, 138, 7175–7181.

110. Zhang, J.; Sun, Y.; Xu, B.; Zhang, H.; Gao, Y.; Song, D. A novel surface plasmon resonance biosensor based on graphene oxide decorated with gold nanorod-antibody conjugates for determination of transferrin. *Biosens. Bioelectron.* 2013, 45, 230–236.

111. Wu, L.; Chu, H.S.; Koh, W.S.; Li, E.P. Highly sensitive graphene biosensors based on surface plasmon resonance. *Opt. Express* 2010, 18, 14395–14400.

112. Kim, Y.K.; Han, S.W.; Min, D.H. Graphene oxide sheath on ag nanoparticle/graphene hybrid films as an antioxidative coating and enhancer of surface-enhanced raman scattering. *ACS Appl. Mater. Interfaces* 2012, 4, 6545–6551.

113. Lu, G.; Li, H.; Liusman, C.; Yin, Z.Y.; Wu, S.X.; Zhang, H. Surface enhanced raman scattering of Ag or Au nanoparticle-decorated reduced graphene oxide for detection of aromatic molecules. *Chem. Sci.* 2011, 2, 1817–1821.
114. Bakhori, N.; Yusof, N.; Abdullah, A.; Hussein, M. Development of a fluorescence resonance energy transfer (fret)-based DNA biosensor for detection of synthetic oligonucleotide of ganoderma boninense. Biosensors 2013, 3, 419–428.

115. Huang, P.-J.J.; Liu, J. Molecular beacon lighting up on graphene oxide. Anal. Chem. 2012, 84, 4192–4198.

116. Zhou, J.; Lu, Q.; Tong, Y.; Wei, W.; Liu, S. Detection of DNA damage by using hairpin molecular beacon probes and graphene oxide. Talanta 2012, 99, 625–630.

117. Al-Ogaidi, I.; Gou, H.L.; Aguilar, Z.P.; Guo, S.W.; Melconian, A.K.; Al-Kazaz, A.K.A.; Meng, F.K.; Wu, N.Q. Detection of the ovarian cancer biomarker CA-125 using chemiluminescence resonance energy transfer to graphene quantum dots. Chem. Commun. 2014, 50, 1344–1346.

118. Xu, W.; Ling, X.; Xiao, J.; Dresselhaus, M.S.; Kong, J.; Xu, H.; Liu, Z.; Zhang, J. Surface Enhanced Raman Spectroscopy on a Flat Graphene Surface. In Proceedings of the National Academy of Sciences, Melbourne, Australia, 12 June 2012; pp. 9281–9286.

119. Liu, X.J.; Cao, L.Y.; Song, W.; Ai, K.L.; Lu, L.H. Functionalizing metal nanostructured film with graphene oxide for ultrasensitive detection of aromatic molecules by surface-enhanced raman spectroscopy. ACS Appl. Mater. Interfaces 2011, 3, 2944–2952.

120. Stiles, P.L.; Dieringer, J.A.; Shah, N.C.; van Duyne, R.R. Surface-enhanced raman spectroscopy. Annu. Rev. Anal. Chem. 2008, 1, 601–626.

121. Moskovits, M. Surface-enhanced spectroscopy. Rev. Mod. Phys. 1985, 57, 783–826.

122. Chan, S.H.; Chen, S.H.; Lin, W.T.; Li, M.C.; Lin, Y.C.; Kuo, C.C. Low-temperature synthesis of graphene on cu using plasma-assisted thermal chemical vapor deposition. Nanoscale Res. Lett. 2013, 8, 285.

123. Cheng, M.; Yang, R.; Zhang, L.C.; Shi, Z.W.; Yang, W.; Wang, D.M.; Xie, G.B.; Shi, D.X.; Zhang, G.Y. Restoration of graphene from graphene oxide by defect repair. Carbon 2012, 50, 2581–2587.

124. Lee, S.W.; Mattevi, C.; Chhowalla, M.; Sankaran, R.M. Plasma-assisted reduction of graphene oxide at low temperature and atmospheric pressure for flexible conductor applications. J. Phys. Chem. Lett. 2012, 3, 772–777.

125. Reina, A.; Jia, X.T.; Ho, J.; Nezhich, D.; Son, H.B.; Bulovic, V.; Dresselhaus, M.S.; Kong, J. Large area, few-layer graphene films on arbitrary substrates by chemical vapor deposition. Nano Lett. 2009, 9, 30–35.

126. Juang, Z.-Y.; Wu, C.-Y.; Lo, C.-W.; Chen, W.-Y.; Huang, C.-F.; Hwang, J.-C.; Chen, F.-R.; Leou, K.-C.; Tsai, C.-H. Synthesis of graphene on silicon carbide substrates at low temperature. Carbon 2009, 47, 2026–2031.

127. Oostinga, J.B.; Heersche, H.B.; Liu, X.; Morpurgo, A.F.; Vandersypen, L.M.K. Gate-induced insulating state in bilayer graphene devices. Nat. Mater. 2008, 7, 151–157.

128. Zhang, Y.; Tang, T.-T.; Girir, C.; Hao, Z.; Martin, M.C.; Zettl, A.; Crommie, M.F.; Shen, Y.R.; Wang, F. Direct observation of a widely tunable bandgap in bilayer graphene. Nature 2009, 459, 820–823.

129. Chen, W.F.; Yan, L.F. Preparation of graphene by a low-temperature thermal reduction at atmosphere pressure. Nanoscale 2010, 2, 559–563.
130. Eda, G.; Fanchini, G.; Chhowalla, M. Large-area ultrathin films of reduced graphene oxide as a transparent and flexible electronic material. Nat. Nanotechnol. 2008, 3, 270–274.
131. Wei, Z.Q.; Wang, D.B.; Kim, S.; Kim, S.Y.; Hu, Y.K.; Yakes, M.K.; Laracuente, A.R.; Dai, Z.T.; Marder, S.R.; Berger, C.; et al. Nanoscale tunable reduction of graphene oxide for graphene electronics. Science 2010, 328, 1373–1376.
132. Moon, I.K.; Lee, J.; Ruoff, R.S.; Lee, H. Reduced graphene oxide by chemical graphitization. Nat. Commun. 2010, 1, 73. doi:10.1038/ncomms1067.
133. Stankovich, S.; Dikin, D.A.; Piner, R.D.; Kohlhaas, K.A.; Kleinhammes, A.; Jia, Y.; Wu, Y.; Nguyen, S.T.; Ruoff, R.S. Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide. Carbon 2007, 45, 1558–1565.
134. Liu, Y.; Huang, L.; Guo, G.L.; Ji, L.C.; Wang, T.; Xie, Y.Q.; Liu, F.; Liu, A.Y. Pulsed laser assisted reduction of graphene oxide as a flexible transparent conducting material. J. Nanosci. Nanotechnol. 2012, 12, 6480–6483.
135. Huang, L.; Liu, Y.; Ji, L.C.; Xie, Y.Q.; Wang, T.; Shi, W.Z. Pulsed laser assisted reduction of graphene oxide. Carbon 2011, 49, 2431–2436.
136. Kumar, N.A.; Nolan, H.; McEvoy, N.; Rezvani, E.; Doyle, R.L.; Lyons, M.E.G.; Duesberg, G.S. Plasma-assisted simultaneous reduction and nitrogen doping of graphene oxide nanosheets. J. Mater. Chem. A 2013, 1, 4431–4435.
137. Yu, Y.; Li, Y.Z.; Pan, Y.X.; Liu, C.J. Fabrication of palladium/graphene oxide composite by plasma reduction at room temperature. Nanoscale Res. Lett. 2012, 7, 234.
138. Levchenko, I.; Kumar, S.; Yajadda, M.M.A.; Han, Z.J.; Furman, S.; Ostrikov, K. Self-organization in arrays of surface-grown nanoparticles: Characterization, control, driving forces. J. Phys. D Appl. Phys. 2011, 44, 174020.
139. Bockrath, M.; Cobden, D.H.; McEuen, P.L.; Chopra, N.G.; Zettl, A.; Thess, A.; Smalley, R.E. Single-electron transport in ropes of carbon nanotubes. Science 1997, 275, 1922–1925.
140. McEuen, P.L.; Park, J.Y. Electron transport in single-walled carbon nanotubes. MRS Bull. 2004, 29, 272–275.
141. Odom, T.W.; Huang, J.L.; Lieber, C.M. Single-walled carbon nanotubes - from fundamental studies to new device concepts. Ann. N. Y. Acad. Sci. 2002, 960, 203–215.
142. Charlier, J.-C.; de Vita, A.; Blase, X.; Car, R. Microscopic growth mechanisms for carbon nanotubes. Science 1997, 275, 647–649.
143. Kwon, Y.K.; Tomanek, D. Electronic and structural properties of multiwall carbon nanotubes. Phys. Rev. B 1998, 58, 16001–16004.
144. Saito, R.; Fujita, M.; Dresselhaus, G.; Dresselhaus, M.S. Electronic-structure of chiral graphene tubules. Appl. Phys. Lett. 1992, 60, 2204–2206.
145. Oh, J.; Yoo, G.; Chang, Y.W.; Kim, H.J.; Jose, J.; Kim, E.; Pyun, J.C.; Yoo, K.H. A carbon nanotube metal semiconductor field effect transistor-based biosensor for detection of amyloid-beta in human serum. Biosens. Bioelectron. 2013, 50, 345–350.
146. Li, B.R.; Chen, C.W.; Yang, W.L.; Lin, T.Y.; Pan, C.Y.; Chen, Y.T. Biomolecular recognition with a sensitivity-enhanced nanowire transistor biosensor. Biosens. Bioelectron. 2013, 45, 252–259.
147. Chang, J.B.; Mao, S.; Zhang, Y.; Cui, S.M.; Steeber, D.A.; Chen, J.H. Single-walled carbon nanotube field-effect transistors with graphene oxide passivation for fast, sensitive, and selective protein detection. Biosens. Bioelectron. 2013, 42, 186–192.

148. Lerner, M.B.; D'Souza, J.; Pazina, T.; Dailey, J.; Goldsmith, B.R.; Robinson, M.K.; Johnson, A.T.C. Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers. ACS Nano 2012, 6, 5143–5149.

149. Croce, R.A.; Vaddiraju, S.; Chan, P.Y.; Seyta, R.; Jain, F.C. Label-free protein detection based on vertically aligned carbon nanotube gated field-effect transistors. Sens. Actuators B Chem. 2011, 160, 154–160.

150. Wang, J.P.; Yau, S.T. Field-effect amperometric immuno-detection of protein biomarker. Biosens. Bioelectron. 2011, 29, 210–214.

151. Kim, J.P.; Hong, S.; Sim, S.J. Apta-biosensors for nonlabeled real time detection of human ige based on carbon nanotube field effect transistors. J. Nanosci. Nanotechnol. 2011, 11, 4182–4187.

152. Mao, S.; Lu, G.H.; Yu, K.H.; Chen, J.H. Specific biosensing using carbon nanotubes functionalized with gold nanoparticle-antibody conjugates. Carbon 2010, 48, 479–486.

153. Kim, S.; Kim, T.G.; Byon, H.R.; Shin, H.J.; Ban, C.; Choi, H.C. Recognition of single mismatched DNA using mutants-immobilized carbon nanotube field effect transistor devices. J. Phys. Chem. B 2009, 113, 12164–12168.

154. Abe, M.; Murata, K.; Ataka, T.; Ifuku, Y.; Matsumoto, K. Selective protein sensing using a carbon nanotube field-effect transistor. J. Nanosci. Nanotechnol. 2009, 9, 1947–1950.

155. Cid, C.C.; Riu, J.; Maroto, A.; Rius, F.X. Detection of human immunoglobulin g at physiological conditions with chemically functionalized carbon nanotube field effect transistors. Curr. Nanosci. 2008, 4, 314–317.

156. Abe, M.; Murata, K.; Kojima, A.; Ifuku, Y.; Shimizu, M.; Ataka, T.; Matsumoto, K. Quantitative detection of protein using a top-gate carbon nanotube field effect transistor. J. Phys. Chem. C 2007, 111, 8667–8670.

157. Kim, J.P.; Lee, B.Y.; Hong, S.; Sim, S.J. Ultrasensitive carbon nanotube-based biosensors using antibody-binding fragments. Anal. Biochem. 2008, 381, 193–198.

158. Maehashi, K.; Matsumoto, K.; Takamura, Y.; Tamiya, E. Aptamer-based label-free immunosensors using carbon nanotube field-effect transistors. Electroanalysis 2009, 21, 1285–1290.

159. Qureshi, A.; Roci, I.; Gurbuz, Y.; Niazi, J.H. An aptamer based competition assay for protein detection using ctaactivated gold-interdigitated capacitor arrays. Biosens. Bioelectron. 2012, 34, 165–170.

160. So, H.-M.; Won, K.; Kim, Y.H.; Kim, B.-K.; Ryu, B.H.; Na, P.S.; Kim, H.; Lee, J.-O. Single-walled carbon nanotube biosensors using aptamers as molecular recognition elements. J. Am. Chem. Soc. 2005, 127, 11906–11907.

161. Lo, Y.-S.; Nam, D.H.; So, H.-M.; Chang, H.; Kim, J.-J.; Kim, Y.H.; Lee, J.-O. Oriented immobilization of antibody fragments on Ni-decorated single-walled carbon nanotube devices. ACS Nano 2009, 3, 3649–3655.

162. Vedala, H.; Chen, Y.A.; Cecioni, S.; Imperty, A.; Vidal, S.; Star, A. Nanoelectronic detection of lectin-carbohydrate interactions using carbon nanotubes. Nano Lett. 2011, 11, 170–175.
163. Yick, S.; Han, Z.J.; Ostrikov, K. Atmospheric microplasma-functionalized 3D microfluidic strips within dense carbon nanotube arrays confine au nanodots for sers sensing. *Chem. Commun.* **2013**, *49*, 2861–2863.

164. Yang, R.H.; Jin, J.Y.; Chen, Y.; Shao, N.; Kang, H.Z.; Xiao, Z.; Tang, Z.W.; Wu, Y.R.; Zhu, Z.; Tan, W.H. Carbon nanotube-quenched fluorescent oligonucleotides: Probes that fluoresce upon hybridization. *J. Am. Chem. Soc.* **2008**, *130*, 8351–8358.

165. Ahn, J.-H.; Kim, J.-H.; Reuel, N.F.; Barone, P.W.; Boghossian, A.A.; Zhang, J.; Yoon, H.; Chang, A.C.; Hilmer, A.J.; Strano, M.S. Label-free, single protein detection on a near-infrared fluorescent single-walled carbon nanotube/protein microarray fabricated by cell-free synthesis. *Nano Lett.* **2011**, *11*, 2743–2752.

166. Jorio, A.; Pimenta, M.A.; Souza, A.G.; Saito, R.; Dresselhaus, G.; Dresselhaus, M.S. Characterizing carbon nanotube samples with resonance raman scattering. *New J. Phys.* **2003**, *5*, doi:10.1088/1367-2630/5/1/139.

167. O’Connell, M.J.; Bachilo, S.M.; Huffman, C.B.; Moore, V.C.; Strano, M.S.; Haroz, E.H.; Rialon, K.L.; Boul, P.J.; Noon, W.H.; Kittrell, C.; *et al*. Band gap fluorescence from individual single-walled carbon nanotubes. *Science* **2002**, *297*, 593–596.

168. Lee, S.; Hahm, M.G.; Vajtai, R.; Hashim, D.P.; Thurakitseree, T.; Chipara, A.C.; Ajayan, P.M.; Hafner, J.H. Utilizing 3D SERS active volumes in aligned carbon nanotube scaffold substrates. *Adv. Mater.* **2012**, *24*, 5261–5266.

169. Goldberg-Oppenheimer, P.; Hutter, T.; Chen, B.A.; Robertson, J.; Hofmann, S.; Mahajan, S. Optimized vertical carbon nanotube forests for multiplex surface-enhanced raman scattering detection. *J. Phys. Chem. Lett.* **2012**, *3*, 3486–3492.

170. Scolari, M.; Mews, A.; Fu, N.; Myalitisin, A.; Assmus, T.; Balasubramanian, K.; Burghard, M.; Kern, K. Surface enhanced raman scattering of carbon nanotubes decorated by individual fluorescent gold particles. *J. Phys. Chem. C* **2008**, *112*, 391–396.

171. D’Acunto, M.; Colantonio, S.; Moroni, D.; Salvetti, O. Detection limit of biomarkers using the near-infrared band-gap fluorescence of single-walled carbon nanotubes. *J. Mod. Opt.* **2010**, *57*, 1695–1699.

172. Jeng, E.S.; Moll, A.E.; Roy, A.C.; Gastala, J.B.; Strano, M.S. Detection of DNA hybridization using the near-infrared band-gap fluorescence of single-walled carbon nanotubes. *Nano Lett.* **2006**, *6*, 371–375.

173. Levchenko, I.; Keidar, M.; Xu, S.Y.; Kersten, H.; Ostrikov, K. Low-temperature plasmas in carbon nanostructure synthesis. *J. Vac. Sci. Technol. B* **2013**, *31*, 050801.

174. Levchenko, I.; Ostrikov, K.; Xu, S. Thermodynamical and plasma-driven kinetic growth of high-aspect-ratio nanostructures: Effect of hydrogen termination. *J. Phys. D Appl. Phys.* **2009**, *42*, 125207.

175. Denysenko, I.B.; Xu, S.; Long, J.D.; Rutkevych, P.P.; Azarenkov, N.A.; Ostrikov, K. Inductively coupled Ar/CH<sub>4</sub>/H<sub>2</sub> plasmas for low-temperature deposition of ordered carbon nanostructures. *J. Appl. Phys.* **2004**, *95*, 2713–2724.

176. Shariat, M.; Hosseini, S.I.; Shokri, B.; Neyts, E.C. Plasma enhanced growth of single walled carbon nanotubes at low temperature: A reactive molecular dynamics simulation. *Carbon* **2013**, *65*, 269–276.
177. Meyyappan, M.; Delzeit, L.; Cassell, A.; Hash, D. Carbon nanotube growth by PECVD: A review. Plasma Sources Sci. Technol. 2003, 12, 205–216.

178. Hofmann, S.; Cantoro, M.; Kleinsorge, B.; Casiraghi, C.; Parvez, A.; Robertson, J.; Ducati, C. Effects of catalyst film thickness on plasma-enhanced carbon nanotube growth. J. Appl. Phys. 2005, 98, 034308.

179. Ostrrikov, K.; Murphy, A.B. Plasma-aided nanofabrication: Where is the cutting edge? J. Phys. D Appl. Phys. 2007, 40, 2223–2241.

180. Han, Z.J.; Levchenko, I.; Yick, S.; Ostrrikov, K. 3-orders-of-magnitude density control of single-walled carbon nanotube networks by maximizing catalyst activation and dosing carbon supply. Nanoscale 2011, 3, 4848–4853.

181. Han, Z.J.; Ostrrikov, K. Uniform, dense arrays of vertically aligned, large-diameter single-walled carbon nanotubes. J. Am. Chem. Soc. 2012, 134, 6018–6024.

182. Ostrrikov, K.; Mehdipour, H. Thin single-walled carbon nanotubes with narrow chirality distribution: Constructive interplay of plasma and gibbs–thomson effects. ACS Nano 2011, 5, 8372–8382.

183. Kumar, S.; Mehdipour, H.; Ostrrikov, K. Plasma-enabled graded nanotube biosensing arrays on a si nanodevice platform: Catalyst-free integration and in situ detection of nucleation events. Adv. Mater. 2013, 25, 69–74.

184. Kumar, S.; Levchenko, I.; Ostrrikov, K.; McLaughlin, J.A. Plasma-enabled, catalyst-free growth of carbon nanotubes on mechanically-written Si features with arbitrary shape. Carbon 2012, 50, 325–329.

185. Ren, Z.F.; Huang, Z.P.; Xu, J.W.; Wang, J.H.; Bush, P.; Siegal, M.P.; Provencio, P.N. Synthesis of large arrays of well-aligned carbon nanotubes on glass. Science 1998, 282, 1105–1107.

186. Qu, L.T.; Du, F.; Dai, L.M. Preferential syntheses of semiconducting vertically aligned single-walled carbon nanotubes for direct use in fets. Nano Lett. 2008, 8, 2682–2687.

187. Robertson, J.; Zhong, G.; Telg, H.; Thomsen, C.; Warner, J.H.; Briggs, G.A.D.; Dettlaff-Weglikowska, U.; Roth, S. Growth and characterization of high-density mats of single-walled carbon nanotubes for interconnects. Appl. Phys. Lett. 2008, 93, 163111.

188. Zheng, G.; Li, Q.; Jiang, K.; Zhang, X.; Chen, J.; Ren, Z.; Fan, S. Transition of single-walled carbon nanotubes from metallic to semiconducting in field-effect transistors by hydrogen plasma treatment. Nano Lett. 2007, 7, 1622–1625.

189. Maehashi, K.; Katsura, T.; Kerman, K.; Takamura, Y.; Matsumoto, K.; Tamiya, E. Label-free protein biosensor based on aptamer-modified carbon nanotube field-effect transistors. Anal. Chem. 2007, 79, 782–787.

190. Khare, B.N.; Wilhite, P.; Quinn, R.C.; Chen, B.; Schingler, R.H.; Tran, B.; Imanaka, H.; So, C.R.; Bauschlicher, C.W., Jr.; Meyyappan, M. Functionalization of carbon nanotubes by ammonia glow-discharge: Experiments and modeling. J. Phys. Chem. B 2004, 108, 8166–8172.

191. Plank, N.O.V.; Forrest, G.A.; Cheung, R.; Alexander, A.J. Electronic properties of n-type carbon nanotubes prepared by CF4 plasma fluorination and amino functionalization. J. Phys. Chem. B 2005, 109, 22096–22101.
192. Malesevic, A.; Vitchev, R.; Schouteden, K.; Volodin, A.; Zhang, L.; van Tendeloo, G.; Vanhulsel, A.; van Haesendonck, C. Synthesis of few-layer graphene via microwave plasma-enhanced chemical vapour deposition. *Nanotechnology* **2008**, *19*, 305604.
193. Wang, Z.; Shoji, M.; Ogata, H. Carbon nanosheets by microwave plasma enhanced chemical vapor deposition in CH$_4$–Ar system. *Appl. Surface Sci.* **2011**, *257*, 9082–9085.
194. Yu, K.H.; Bo, Z.; Lu, G.H.; Mao, S.; Cui, S.M.; Zhu, Y.W.; Chen, X.Q.; Ruoff, R.S.; Chen, J.H. Growth of carbon nanowalls at atmospheric pressure for one-step gas sensor fabrication. *Nanoscale Res. Lett.* **2011**, *6*, 202.
195. Zhu, M.Y.; Outlaw, R.A.; Bagge-Hansen, M.; Chen, H.J.; Manos, D.M. Enhanced field emission of vertically oriented carbon nanosheets synthesized by C$_2$H$_2$/H$_2$ plasma enhanced CVD. *Carbon* **2011**, *49*, 2526–2531.
196. Wu, Y.H. Effects of localized electric field on the growth of carbon nanowalls. *Nano Lett.* **2002**, *2*, 355–359.
197. Yu, K.H.; Wang, P.X.; Lu, G.H.; Chen, K.H.; Bo, Z.; Chen, J.H. Patterning vertically oriented graphene sheets for nanodevice applications. *J. Phys. Chem. Lett.* **2011**, *2*, 537–542.
198. Mao, S.; Yu, K.H.; Chang, J.B.; Steeber, D.A.; Ocola, L.E.; Chen, J.H. Direct growth of vertically-oriented graphene for field-effect transistor biosensor. *Sci. Rep. (UK)* **2013**, *3*, 1696.
199. Akhavan, O.; Ghaderi, E.; Rahighi, R. Toward single-DNA electrochemical biosensing by graphene nanowalls. *ACS Nano* **2012**, *6*, 2904–2916.
200. Vansweevelt, R.; Malesevic, A.; van Gompel, M.; Vanhulsel, A.; Wenmackers, S.; D’Haen, J.; Vermeeren, V.; Ameloot, M.; Michiels, L.; van Haesendonck, C.; *et al*. Biological modification of carbon nanowalls with DNA strands and hybridization experiments with complementary and mismatched DNA. *Chem. Phys. Lett.* **2010**, *485*, 196–201.
201. Seo, D.H.; Rider, A.E.; Kumar, S.; Randeniya, L.K.; Ostrikov, K. Vertical graphene gas- and bio-sensors via catalyst-free, reactive plasma reforming of natural honey. *Carbon* **2013**, *60*, 221–228.
202. Seo, D.H.; Kumar, S.; Rider, A.E.; Han, Z.J.; Ostrikov, K. Deterministic control of structural and optical properties of plasma-grown vertical graphene nanosheet networks via nitrogen gas variation. *Opt. Mater. Express* **2012**, *2*, 700–707.
203. Rout, C.S.; Kumar, A.; Fisher, T.S. Carbon nanowalls amplify the surface-enhanced raman scattering from ag nanoparticles. *Nanotechnology* **2011**, *22*, 395704.
204. Wu, Y.; Qiao, P.; Chong, T.; Shen, Z. Carbon nanowalls grown by microwave plasma enhanced chemical vapor deposition. *Adv. Mater.* **2002**, *14*, 64–67.
205. Wang, J.J.; Zhu, M.Y.; Outlaw, R.A.; Zhao, X.; Manos, D.M.; Holloway, B.C.; Mammana, V.P. Free-standing subnanometer graphite sheets. *Appl. Phys. Lett.* **2004**, *85*, 1265–1267.
206. Mori, T.; Hiramatsu, M.; Yamakawa, K.; Takeda, K.; Hori, M. Fabrication of carbon nanowalls using electron beam excited plasma-enhanced chemical vapor deposition. *Diam. Relat. Mater.* **2008**, *17*, 1513–1517.
207. Sato, G.; Morio, T.; Kato, T.; Hatakeyama, R. Fast growth of carbon nanowalls from pure methane using helicon plasma-enhanced chemical vapor deposition. *Jpn. J. Appl. Phys.* **2006**, *45*, 5210–5212.
208. Kurita, S.; Yoshimura, A.; Kawamoto, H.; Uchida, T.; Kojima, K.; Tachibana, M.; Molina-Morales, P.; Nakai, H. Raman spectra of carbon nanowalls grown by plasma-enhanced chemical vapor deposition. *J. Appl. Phys.* **2005**, *97*, 104320.

209. Zhang, H.; Yoshimura, I.; Kusano, E.; Kogure, T.; Kinbara, A. Formation of carbon nano-flakes by RF magnetron sputtering method. *SHINKU* **2004**, *47*, 82–86.

210. Itoh, T. Synthesis of carbon nanowalls by hot-wire chemical vapor deposition. *Thin Solid Films* **2011**, *519*, 4589–4593.

211. Giorgi, L.; Makris, T.D.; Giorgi, R.; Lisi, N.; Salernitano, E. Electrochemical properties of carbon nanowalls synthesized by HF-CVD. *Sens. Actuators B Chem.* **2007**, *126*, 144–152.

212. Wang, B.B.; Ostrikov, K.; van der Laan, T.; Zheng, K.; Wang, J.J.; Yan, Y.P.; Quan, X.J. Carbon nanorods and graphene-like nanosheets by hot filament CVD: Growth mechanisms and electron field emission. *J. Mater. Chem. C* **2013**, *1*, 7703–7708.

213. Seo, D.H.; Han, Z.J.; Kumar, S.; Ostrikov, K. Structure-controlled, vertical graphene-based, binder-free electrodes from plasma-reformed butter enhance supercapacitor performance. *Adv. Energy Mater.* **2013**, *3*, 1316–1323.

214. Seo, D.H.; Rider, A.E.; Han, Z.J.; Kumar, S.; Ostrikov, K. Plasma break-down and re-build: Same functional vertical graphenes from diverse natural precursors. *Adv. Mater.* **2013**, *25*, 5638–5642.

215. Zhu, M.Y.; Wang, J.J.; Holloway, B.C.; Outlaw, R.A.; Zhao, X.; Hou, K.; Shuththanandan, V.; Manos, D.M. A mechanism for carbon nanosheet formation. *Carbon* **2007**, *45*, 2229–2234.

216. Tai, L.M.; Bilousova, T.; Jungbauer, L.; Roeseke, S.K.; Youmans, K.L.; Yu, C.; Poon, W.W.; Cornwell, L.B.; Miller, C.A.; Vinters, H.V.; *et al*. Levels of soluble apolipoprotein E/Amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and alzheimer disease in a transgenic mouse model and human samples. *J. Biol. Chem.* **2013**, *288*, 5914–5926.

217. Glabe, C.G. Structural classification of toxic amyloid oligomers. *J. Biol. Chem.* **2008**, *283*, 29639–29643.

218. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **2003**, *300*, 486–489.

219. Gubbens, J.; Ruijter, E.; de Fays, L.E.V.; Damen, J.M.A.; de Kruijff, B.; Slijper, M.; Rijkers, D.T.S.; Liskamp, R.M.J.; de Kroon, A.I.P.M. Photocrosslinking and click chemistry enable the specific detection of proteins interacting with phospholipids at the membrane interface. *Chem. Biol.* **2009**, *16*, 3–14.

220. Kim, Y.S.; Lee, J.H.; Ryu, J.; Kim, D.J. Multivalent & multifunctional ligands to beta-amyloid. *Curr. Pharm. Des.* **2009**, *15*, 637–658.

221. Kole, R.; Krainer, A.R.; Altman, S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. *Nat. Rev. Drug Discov.* **2012**, *11*, 125–140.

222. Yan, R.; Vassar, R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. *Lancet Neurol.* **2014**, *13*, 319–329.

223. Vom Berg, J.; Prokop, S.; Miller, K.R.; Obst, J.; Kalin, R.E.; Lopategui-Cabezas, I.; Wegner, A.; Mair, F.; Schipke, C.G.; Peters, O.; *et al*. Inhibition of IL-12/IL-23 signaling reduces alzheimer’s disease-like pathology and cognitive decline. *Nat. Med.* **2012**, *18*, 1812–1819.
224. Han, Z.J.; Levchenko, I.; Kumar, S.; Yajadda, M.M.A.; Yick, S.; Seo, D.H.; Martin, P.J.; Peel, S.; Kuncic, Z.; Ostrikov, K. Plasma nanofabrication and nanomaterials safety. *J. Phys. D Appl. Phys.* 2011, 44, 174019.

225. Yang, T.; Guan, Q.; Meng, L.; Yang, R.R.; Li, Q.H.; Jiao, K. A simple preparation method for large-area, wavy graphene oxide nanowalls and their application to freely switchable impedimetric DNA detection. *RSC Adv.* 2013, 3, 22430–22435.

226. Shang, N.G.; Papakonstantinou, P.; McMullan, M.; Chu, M.; Stamboulis, A.; Potenza, A.; Dhesi, S.S.; Marchetto, H. Catalyst-free efficient growth, orientation and biosensing properties of multilayer graphene nanoflake films with sharp edge planes. *Adv. Funct. Mater.* 2008, 18, 3506–3514.

227. Claussen, J.C.; Kumar, A.; Jaroch, D.B.; Khawaja, M.H.; Hibbard, A.B.; Porterfield, D.M.; Fisher, T.S. Nanostructuring platinum nanoparticles on multilayered graphene petal nanosheets for electrochemical biosensing. *Adv. Funct. Mater.* 2012, 22, 3399–3405.

228. Kurkina, T.; Vlandas, A.; Ahmad, A.; Kern, K.; Balasubramanian, K. Label-free detection of few copies of DNA with carbon nanotube impedance biosensors. *Angew. Chem. Int. Ed.* 2011, 50, 3710–3714.

229. Martínez, M.T.; Tseng, Y.-C.; Ormategui, N.; Loinaz, I.; Eritja, R.; Bokor, J. Label-free DNA biosensors based on functionalized carbon nanotube field effect transistors. *Nano Lett.* 2009, 9, 530–536.

230. Deng, S.; Jian, G.; Lei, J.; Hu, Z.; Ju, H. A glucose biosensor based on direct electrochemistry of glucose oxidase immobilized on nitrogen-doped carbon nanotubes. *Biosens. Bioelectron.* 2009, 25, 373–377.

231. Rakhi, R.B.; Sethupathi, K.; Ramaprabhu, S. A glucose biosensor based on deposition of glucose oxidase onto crystalline gold nanoparticle modified carbon nanotube electrode. *J. Phys. Chem. B* 2009, 113, 3190–3194.

232. Zhu, L.; Luo, L.; Wang, Z. DNA electrochemical biosensor based on thionine-graphene nanocomposite. *Biosens. Bioelectron.* 2012, 35, 507–511.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).